{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "cc104c19bfad9c33fd4255a85608c566",
    "title": "Q1 Review: Evo FDA approval on the horizon?",
    "source_uri": "25.9月 普通个人版/9.2 普通个人版/Barclays/Elekta AB Q1 Review Evo FDA approval on the horizonElekta AB Q1 Review Evo FDA approval on the horizon_2025-08-29",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T15:05:44.133589",
      "extracted_at": "2025-10-26T15:05:44.133596"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 21,
        "successful_pages": 21,
        "date": "2025-08-29",
        "publication": "25.9月 普通个人版/9.2 普通个人版/Barclays",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 10,
          "removed_paragraphs": 37,
          "reduction_ratio": 0.24853737606684123
        },
        "input_relative_path": "25.9月 普通个人版/9.2 普通个人版/Barclays"
      }
    }
  },
  "passages": [
    {
      "passage_id": "b38ea0c366cae2f3",
      "text": "Q1 was a mixed print, in our view, with a stronger EBIT print marred by softer Q2 expectations, resulting in shares being down c.- 4.7% (vs. SXDP c.- 0.8%). No FDA approval for Evo yet, although management are hopefully this will be a H1 event.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "647444ab8f329a4f",
      "text": "We update our numbers following the company's Q1 results (see Q1 first take: EBIT beat, Q2 softer, 28 Aug). The quarter was characterised by a beat on EBIT, with sales broadly in line supported entirely by momentum in EMEA, which grew c.+15% in ccy, driven by Evo (although we note an easy comparison base of - 12%). Management expects the US to continue to be a drag in Q2 though are hopeful of an FDA approval of Evo before fiscal H2 and don't view approval as a necessity to meet guidance this year. Elsewhere, China order momentum is improving with a sales recovery expected in H2. Overall, we make 1- 2% FY EBIT cuts and lower our expectations for Q2 following management commentary around softer US and China and expect the ramp in H2 to be closely watched. We reiterate our UW rating and prefer Siemens Healthineers (OW) (see: 2025 outlook: 5 themes for '25, 21 November).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "8593b517fed14d93",
      "text": "Key takes from management's presentation: 1) Q2 guidance: Organic growth is not expected in Q2 (versus consensus +4.7% ccy growth) given sales pressure stemming from both the US and China. On gross margin, a similar 90bps drag as in Q1 is anticipated in Q2, although the FX headwind (100bps in Q1) should gradually improve. 2) APAC: In China, the orderbook remains below pre- pandemic levels, although management is seeing a pick- up in orders, which is expected to continue. Whilst sales are expected to decline in Q2, growth is expected to recover in fiscal H2. In India, weakness was attributed to the lumpiness of orders by quarters, with management citing the market remains positive and attractive long term, noting below 1 LINAC per million in India versus 12 in the US. 3) US: Management continues to work towards FDA approval of Evo. Although the timeline remains unclear, they are hopeful of approval before H2 and noted that whilst approval is assumed in guidance, there are other geographic growth drivers that underpin guidance with US Evo approval not a necessity. US softness in Q1 may have also been partially attributable to market weakness, not just order postponement ahead of Evo approval.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "c9f458324b40afe7",
      "text": "R R 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 3 1 1 1 1 1 1 1 1 1 1 4 1 1 1 1 1 1 1 1 1 5 1 1 1 1 1 1 1 1 1 6 1 1 1 1 1 1 1 1 1 7 1 1 1 1 1 1 1 1 1 8 1 1 1 1 1 1 1 1 1 9 1 1 1 1 1 1 1 1 1 10 1 1 1 1 1 1 1 1 1 11 1 1 1 1 1 1 1 1 12 1 1 1 1 1 1 1 1 13 1 1 1 1 1 1 1 1 14 1 1 1 1 1 1 1 1 15 1 1 1 1 1 1 1 1 16 1 1 1 1 1 1 1 1 17 1 1 1 1 1 1 1 1 18 1 1 1 1 1 1 1 1 19 1 1 1 1 1 1 1 1 20 1 1 1 1 1 1 1 1 21 1 1 1 1 1 1 1 1 22 1 1 1 1 1 1 1 1 23 1 1 1 1 1 1 1 1 24 1 1 1 1 1 1 1 1 25 1 1 1 1 1 1 1 1 26 1 1 1 1 1 1 1 1 27 1 1 1 1 1 1 1 1 28 1 1 1 1 1 1 1 1 29 1 1 1 1 1 1 1 1 30 1 1 1 1 1 1 1 1 31 1 1 1 1 1 1 1 1 32 1 1 1 1 1 1 1 1 33 1 1 1 1 1 1 1 1 34 1 1 1 1 1 1 1 1 35 1 1 1 1 1 1 1 1 36 1 1 1 1 1 1 1 1 37 1 1 1 1 1 1 1 1 38 1 1 1 1 1 1 1 1 39 1 1 1 1 1 1 1 1 40 1 1 1 1 1 1 1 1 41 1 1 1 1 1 1 1 1 42 1 1 1 1 1 1 1 1 43 1 1 1 1 1 1 1 1 44 1 1 1 1 1 1 1 1 45 1 1 1 1 1 1 1 1 46 1 1 1 1 1 1 1 1 47 1 1 1 1 1 1 1 1 48 1 1 1 1 1 1 1 1 49 1 1 1 1 1 1 1 1 50 1 1 1 1 1 1 1 1 51 1 1 1 1 1 1 1 1 52 1 1 1 1 1 1 1 1 53 1 1 1 1 1 1 1 1 54 1 1 1 1 1 1 1 1 55 1 1 1 1 1 1 1 1 56 1 1 1 1 1 1 1 1 57 1 1 1 1 1 1 1 1 58 1 1 1 1 1 1 1 1 59 1 1 1 1 1 1 1 1 60 1 1 1 1 1 1 1 1 61 1 1 1 1 1 1 1 1 62 1 1 1 1 1 1 1 1 63 1 1 1 1 1 1 1 1 64 1 1 1 1 1 1 1 1 65 1 1 1 1 1 1 1 1 66 1 1 1 1 1 1 1 1 67 1 1 1 1 1 1 1 1 68 1 1 1 1 1 1 1 1 69 1 1 1 1 1 1 1 1 70 1 1 1 1 1 1 1 1 71 1 1 1 1 1 1 1 1 72 1 1 1 1 1 1 1 1 73 1 1 1 1 1 1 1 1 74 1 1 1 1 1 1 1 1 75 1 1 1 1 1 1 1 1 76 1 1 1 1 1 1 1 1 77 1 1 1 1 1 1 1 1 78 1 1 1 1 1 1 1 1 79 1 1 1 1 1 1 1 1 80 1 1 1 1 1 1 1 1 81 1 1 1 1 1 1 1 1 82 1 1 1 1 1 1 1 1 83 1 1 1 1 1 1 1 1 84 1 1 1 1 1 1 1 1 85 1 1 1 1 1 1 1 1 86 1 1 1 1 1 1 1 1 87 1 1 1 1 1 1 1 1 88 1 1 1 1 1 1 1 1 89 1 1 1 1 1 1 1 1 90 1 1 1 1 1 1 1 1 91 1 1 1 1 1 1 1 1 92 1 1 1 1 1 1 1 1 93 1 1 1 1 1 1 1 1 94 1 1 1 1 1 1 1 1 95 1 1 1 1 1 1 1 1 96 1 1 1 1 1 1 1 1 97 1 1 1 1 1 1 1 1 98 1 1 1 1 1 1 1 1 99 1 1 1 1 1 1 1 1 100 1 1 1 1 1 1 1 1 101 1 1 1 1 1 1 1 1 102 1 1 1 1 1 1 1 1 103 1 1 1 1 1 1 1 1 104 1 1 1 1 1 1 1 1 105 1 1 1 1 1 1 1 1 106 1 1 1 1 1 1 1 1 107 1 1 1 1 1 1 1 1 108 1 1 1 1 1 1 1 1 109 1 1 1 1 1 1 1 1 110 1 1 1 1 1 1 1 1 111 1 1 1 1 1 1 1 1 112 1 1 1 1 1 1 1 1 113 1 1 1 1 1 1 1 1 114 1 1 1 1 1 1 1 1 115 1 1 1 1 1 1 1 1 116 1 1 1 1 1 1 1 1 117 1 1 1 1 1 1 1 1 118 1 1 1 1 1 1 1 1 119 1 1 1 1 1 1 1 1 120 1 1 1 1 1 1 1 1 121 1 1 1 1 1 1 1 1 122 1 1 1 1 1 1 1 1 123 1 1 1 1 1 1 1 1 124 1 1 1 1 1 1 1 1 125 1 1 1 1 1 1 1 1 126 1 1 1 1 1 1 1 1 127 1 1 1 1 1 1 1 1 128 1 1 1 1 1 1 1 1 129 1 1 1 1 1 1 1 1 130 1 1 1 1 1 1 1 1 131 1 1 1 1 1 1 1 1 132 1 1 1 1 1 1 1 1 133 1 1 1 1 1 1 1 1 134 1 1 1 1 1 1 1 1 135 1 1 1 1 1 1 1 1 136 1 1 1 1 1 1 1 1 137 1 1 1 1 1 1 1 1 138 1 1 1 1 1 1 1 1 139 1 1 1 1 1 1 1 1 140 1 1 1 1 1 1 1 1 141 1 1 1 1 1 1 1 1 142 1 1 1 1 1 1 1 1 143 1 1 1 1 1 1 1 1 144 1 1 1 1 1 1 1 1 145 1 1 1 1 1 1 1 1 146 1 1 1 1 1 1 1 1 147 1 1 1 1 1 1 1 1 148 1 1 1 1 1 1 1 1 149 1 1 1 1 1 1 1 1 150 1 1 1 1 1 1 1 1 151 1 1 1 1 1 1 1 1 152 1 1 1 1 1 1 1 1 153 1 1 1 1 1 1 1 1 154 1 1 1 1 1 1 1 1 155 1 1 1 1 1 1 1 1 156 1 1 1 1 1 1 1 1 157 1 1 1 1 1 1 1 1 158 1 1 1 1 1 1 1 1 159 1 1 1 1 1 1 1 1 160 1 1 1 1 1 1 1 1 161 1 1 1 1 1 1 1 1 162 1 1 1 1 1 1 1 1 163 1 1 1 1 1 1 1 1 164 1 1 1 1 1 1 1 1 165 1 1 1 1 1 1 1 1 166 1 1 1 1 1 1 1 1 167 1 1 1 1 1 1 1 1 168 1 1 1 1 1 1 1 1 169 1 1 1 1 1 1 1 1 170 1 1 1 1 1 1 1 1 171 1 1 1 1 1 1 1 1 172 1 1 1 1 1 1 1 1 173 1 1 1 1 1 1 1 1 174 1 1 1 1 1 1 1 1 175 1 1 1 1 1 1 1 1 176 1 1 1 1 1 1 1 1 177 1 1 1 1 1 1 1 1 178 1 1 1 1 1 1 1 1 179 1 1 1 1 1 1 1 1 180 1 1 1 1 1 1 1 1 181 1 1 1 1 1 1 1 1 182 1 1 1 1 1 1 1 1 183 1 1 1 1 1 1 1 1 184 1 1 1 1 1 1 1 1 185 1 1 1 1 1 1 1 1 186 1 1 1 1 1 1 1 1 187 1 1 1 1 1 1 1 1 188 1 1 1 1 1 1 1 1 189 1 1 1 1 1 1 1 1 190 1 1 1 1 1 1 1 1 191 1 1 1 1 1 1 1 1 192 1 1 1 1 1 1 1 1 193 1 1 1 1 1 1 1 1 194 1 1 1 1 1 1 1 1 195 1 1 1 1 1 1 1 1 196 1 1 1 1 1 1 1 1 197 1 1 1 1 1 1 1 1 198 1 1 1 1 1 1 1 1 199 1 1 1 1 1 1 1 1 200 1 1 1 1 1 1 1 1 201 1 1 1 1 1 1 1 1 202 1 1 1 1 1 1 1 1 203 1 1 1 1 1 1 1 1 204 1 1 1 1 1 1 1 1 205 1 1 1 1 1 1 1 1 206 1 1 1 1 1 1 1 1 207 1 1 1 1 1 1 1 1 208 1 1 1 1 1 1 1 1 209 1 1 1 1 1 1 1 1 210 1 1 1 1 1 1 1 1 211 1 1 1 1 1 1 1 1 212 1 1 1 1 1 1 1 1 213 1 1 1 1 1 1 1 1 214 1 1 1 1 1 1 1 1 215 1 1 1 1 1 1 1 1 216 1 1 1 1 1 1 1 1 217 1 1 1 1 1 1 1 1 218 1 1 1 1 1 1 1 1 219 1 1 1 1 1 1 1 1 220 1 1 1 1 1 1 1 1 221 1 1 1 1 1 1 1 1 222 1 1 1 1 1 1 1 1 223 1 1 1 1 1 1 1 1 224 1 1 1 1 1 1 1 1 225 1 1 1 1 1 1 1 1 226 1 1 1 1 1 1 1 1 227 1 1 1 1 1 1 1 1 228 1 1 1 1 1 1 1 1 229 1 1 1 1 1 1 1 1 230 1 1 1 1 1 1 1 1 231 1 1 1 1 1 1 1 1 232 1 1 1 1 1 1 1 1 233 1 1 1 1 1 1 1 1 234 1 1 1 1 1 1 1 1 235 1 1 1 1 1 1 1 1 236 1 1 1 1 1 1 1 1 237 1 1 1 1 1 1 1 1 238 1 1 1 1 1 1 1 1 239 1 1 1 1 1 1 1 1 240 1 1 1 1 1 1 1 1 241 1 1 1 1 1 1 1 1 242 1 1 1 1 1 1 1 1 243 1 1 1 1 1 1 1 1 244 1 1 1 1 1 1 1 1 245 1 1 1 1 1 1 1 1 246 1 1 1 1 1 1 1 1 247 1 1 1 1 1 1 1 1 248 1 1 1 1 1 1 1 1 249 1 1 1 1 1 1 1 1 250 1 1 1 1 1 1 1 1 251 1 1 1 1 1 1 1 1 252 1 1 1 1 1 1 1 1 253 1 1 1 1 1 1 1 1 254 1 1 1 1 1 1 1 1 255 1 1 1 1 1 1 1 1 256 1 1 1 1 1 1 1 1 257 1 1 1 1 1 1 1 1 258 1 1 1 1 1 1 1 1 259 1 1 1 1 1 1 1 1 260 1 1 1 1 1 1 1 1 261 1 1 1 1 1 1 1 1 262 1 1 1 1 1 1 1 1 263 1 1 1 1 1 1 1 1 264 1 1 1 1 1 1 1 1 265 1 1 1 1 1 1 1 1 266 1 1 1 1 1 1 1 1 267 1 1 1 1 1 1 1 1 268 1 1 1 1 1 1 1 1 269 1 1 1 1 1 1 1 1 270 1 1 1 1 1 1 1 1 271 1 1 1 1 1 1 1 1 272 1 1 1 1 1 1 1 1 273 1 1 1 1 1 1 1 1 274 1 1 1 1 1 1 1 1 275 1 1 1 1 1 1 1 1 276 1 1 1 1 1 1 1 1 277 1 1 1 1 1 1 1 1 278 1 1 1 1 1 1 1 1 279 1 1 1 1 1 1 1 1 280 1 1 1 1 1 1 1 1 281 1 1 1 1 1 1 1 1 282 1 1 1 1 1 1 1 1 283 1 1 1 1 1 1 1 1 284 1 1 1 1 1 1 1 1 285 1 1 1 1 1 1 1 1 286 1 1 1 1 1 1 1 1 287 1 1 1 1 1 1 1 1 288 1 1 1 1 1 1 1 1 289 1 1 1 1 1 1 1 1 290 1 1 1 1 1 1 1 1 291 1 1 1 1 1 1 1 1 292 1 1 1 1 1 1 1 1 293 1 1 1 1 1 1 1 1 1 294 1 1 1 1 1 1 1 1 295 1 1 1 1 1 1 1 1 296 1 1 1 1 1 1 1 1 1 297 1 1 1 1 1 1 1 1 1 298 1 1 1 1 1 1 1 1 1 299 1 1 1 1 1 1 1 1 1 300 1 1 1 1 1 1 1 1 301 1 1 1 1 1 1 1 1 302 1 1 1 1 1 1 1 1 303 1 1 1 1 1 1 1 1 304 1 1 1 1 1 1 1 1 305 1 1 1 1 1 1 1 1 306 1 1 1 1 1 1 1 1 307 1 1 1 1 1 1 1 1 308 1 1 1 1 1 1 1 1 309 1 1 1 1 1 1 1 1 310 1 1 1 1 1 1 1 1 311 1 1 1 1 1 1 1 1 312 1 1 1 1 1 1 1 1 313 1 1 1 1 1 1 1 1 314 1 1 1 1 1 1 1 1 315 1 1 1 1 1 1 1 1 316 1 1 1 1 1 1 1 1 317 1 1 1 1 1 1 1 1 318 1 1 1 1 1 1 1 1 319 1 1 1 1 1 1 1 1 320 1 1 1 1 1 1 1 1 321 1 1 1 1 1 1 1 1 322 1 1 1 1 1 1 1 1 323 1 1 1 1 1 1 1 1 324 1 1 1 1 1 1 1 1 325 1 1 1 1 1 1 1 1 326 1 1 1 1 1 1 1 1 327 1 1 1 1 1 1 1 1 328 1 1 1 1 1 1 1 1 329 1 1 1 1 1 1 1 1 330 1 1 1 1 1 1 1 1 331 1 1 1 1 1 1 1 1 332 1 1 1 1 1 1 1 1 333 1 1 1 1 1 1 1 1 334 1 1 1 1 1 1 1 1 335 1 1 1 1 1 1 1 1 336 1 1 1 1 1 1 1 1 337 1 1 1 1 1 1 1 1 338 1 1 1 1 1 1 1 1 339 1 1 1 1 1 1 1 1 340 1 1 1 1 1 1 1 1 341 1 1 1 1 1 1 1 1 342 1 1 1 1 1 1 1 1 343 1 1 1 1 1 1 1 1 344 1 1 1 1 1 1 1 1 345 1 1 1 1 1 1 1 1 346 1 1 1 1 1 1 1 1 347 1 1 1 1 1 1 1 1 348 1 1 1 1 1 1 1 1 349 1 1 1 1 1 1 1 1 350 1 1 1 1 1 1 1 1 351 1 1 1 1 1 1 1 1 352 1 1 1 1 1 1 1 1 353 1 1 1 1 1 1 1 1 354 1 1 1 1 1 1 1 1 355 1 1 1 1 1 1 1 1 356 1 1 1 1 1 1 1 1 357 1 1 1 1 1 1 1 1 358 1 1 1 1 1 1 1 1 359 1 1 1 1 1 1 1 1 360 1 1 1 1 1 1 1 1 361 1 1 1 1 1 1 1 1 362 1 1 1 1 1 1 1 1 363 1 1 1 1 1 1 1 1 364 1 1 1 1 1 1 1 1 365 1 1 1 1 1",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "fcce3395b0b8968c",
      "text": "**Valuation and estimates:** We make c.1-2% cuts to EBIT and c.3-4% cuts to EPS, partly driven by higher interest expense. As a result, we lower our PT to SEK 48 (from SEK 49.5). Our valuation is based on a valuation of \\(\\sim 12x\\) PE and 8x EV/EBITDA on Apr'26E, applying a \\(\\sim 30\\%\\) discount to peers. We view a discount to peers as justified given Elekta's poor track record of execution and downside risk to margins over the medium term.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "b36f851348f74cd3",
      "text": "EKTAb.ST: Financial and Valuation Metrics EPS (SEK)",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "74e13d4e09c2f7fb",
      "text": "FY Apr20242025202620272028EPS3.62A3.08A3.33E3.68E4.03EPrevious EPS3.62A3.08A3.47E3.81E4.16EConsensus EPS3.41A0.62A3.49E3.98E4.51EP/E13.515.914.713.312.1",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "b7e47f7227e8dbec",
      "text": "Consensus numbers are from Bloomberg received on 28-Aug-2025; 12:50 GMT",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "2caceff19cc2b04c",
      "text": "Source: Barclays Research",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f5f1eec0bf9acf29",
      "text": "- - - - - - - - - - - - - - - - - - - - - -",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "bca837cdede52d3d",
      "text": "- - - - - - - - - - - - - - - - - - - - - -",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "6412729acd73fb40",
      "text": "European Medical Technology & Services",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "707d13daa20b58b8",
      "text": "European Medical Technology &amp;amp; ServicesElekta AB (EKTAB.ST)Income statement (SEKmn)2025A2026E2027E2028ECAGRPrice (27-Aug-2025)Revenue18,01617,59618,02818,9161.6%Price TargetGross profit6,8106,5286,8617,2382.1%EBITDA (adj)3963,4983,5903,8023.8%EBIT (adj)1,0971,9872,1542,3173.4%Pre-tax income (adj)1,6971,6331,8041,9775.2%Net income (adj)1,1821,2751,4071,5429.3%EPS (adj) (SEK)3.083.333.684.039.3%Diluted shares (mn)3823823823820.0%DPS (SEK)2.402.402.402.420.2%Margin and return data2025A2026E2027E2028EAverageGross margin (%)37.837.938.138.338.0EBIT (adj) margin (%)11.611.511.912.211.8Pre-tax (adj) margin (%)9.49.510.010.59.8Net (adj) margin (%)6.67.47.88.27.5ROCE (%)16.516.617.017.216.8ROE (%)13.413.614.314.714.0Cash flow and balance sheet (SEKmn)2025A2026E2027E2028ECAGRChange in working capital-203-394-230-255N/ACash flow from operations2,6262,0752,6672,8272.5%Capital expenditure-1,570-1,399-1,382-1,355N/AEquity free cash flow7088681,2311,41726.0%Tangible fixed assets901864822778-4.8%Intangible fixed assets11,91712,35712,58012,7412.3%Cash and equivalents2,9552,6662,7442,9970.5%Total assets28,97729,49330,05830,7672.0%Short and long-term debt6,3736,5766,5766,5761.1%Other long-term liabilities6256346346340.5%Total liabilities20,12920,12120,19620,2800.2%Total invested capital15,22115,94816,43817,0633.9%Net debt/(funds)4,6125,0734,9954,7420.9%Minorities454646460.7%Shareholders&#x27; equity8,8039,3269,81610,4415.9%Valuation and leverage metrics2025A2026E2027E2028EAverageTotal debt/capital (%)30.431.930.527.930.2Net debt/equity (%)52.454.450.945.450.8P/E (adj) (x)15.914.713.312.114.0EV/sales (x)1.31.41.31.21.3EV/EBITDA (adj) (x)6.97.06.66.26.7Equity FCF yield (%)3.84.66.67.65.6P/FCF (x)26.421.515.213.219.1P/BV (x)2.12.01.91.82.0Dividend yield (%)4.94.94.94.94.8",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "4387bda9cd9c2177",
      "text": "Note: FY End Apr Source: Company data, Bloomberg, Barclays Research",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "68c7a9d64f277a91",
      "text": "We continue to see risks skewed to the downside",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "a9874b667ec94670",
      "text": "(in SEKm, Apr Y/E)FY 22/23AQ1 24/25Q2 24/25Q3 24/25Q4 24/25FY 24/25Q1 25/26Q2 25/26Q3 25/26Q4 25/26FY 25/26EFY 25/26EFY 26/27EFY 27/28EP&amp;amp;LNet sales16,8703,8254,3414,6955,15618,0163,6464,0924,3605,12717,22618,02818,916Gross income adjusted6,4201,4451,5511,7402,0756,8101,3501,4951,6212,0626,5286,8617,238Margin38.1%37.8%35.7%37.1%40.2%37.8%37.0%36.5%37.2%40.2%37.9%38.1%38.3%EBITDA adjusted2,9086007458861,1653,3965487378651,2223,3733,5903,802Margin17.2%15.7%17.2%18.9%22.6%18.8%15.0%18.0%19.8%23.8%19.6%19.9%20.1%EBIT adjusted1,7432834235488432,0972353855078601,9872,1542,317Margin10.3%7.4%9.7%11.7%16.3%11.6%6.4%9.4%11.6%16.8%11.5%11.9%12.2%Adj. net income1,1871552433534301,1821182323236031,2751,4071,542EPS adjusted (diluted)3.100.410.630.941.113.080.310.600.841.583.333.684.03Net salesAmericas5,2391,2411,2121,3591,3715,1831,0711,0751,2091,3564,7114,8815,083EMEA5,9071,3141,5971,6552,0146,5801,4431,6701,6542,0106,7777,0847,407APAC5,7241,2701,5321,6811,7716,2531,1321,3481,4971,7615,7386,0636,427Group16,8703,8254,3414,6955,15618,0163,6464,0924,3605,12717,22618,02818,916Sales ccy growth, %Americas5.0%16.0%-8.0%-5.0%-6.0%-2.0%-4.0%-3.4%3.2%4.9%0.4%3.9%4.1%EMEA3.0%-12.0%-5.0%5.0%16.0%1.0%15.0%7.0%4.1%-0.4%5.6%4.6%4.6%APAC5.0%3.0%0.0%6.0%5.0%4.0%-4.0%-3.5%3.3%6.0%0.9%6.0%6.0%Group4.0%1.0%-4.0%2.0%6.0%1.0%3.0%0.4%3.6%3.2%2.5%4.9%4.9%Adj. EBITAmericas2,0934984525634571,9673743744815061,7351,8121,897EMEA2,0004245165908042,3335366156038062,5602,6972,835APAC1,9104455535596762,2334014885256742,0882,2242,370Global costs-4,259-1,084-1,098-1,164-1,094-4,436-1,076-1,091-1,101-1,127-4,395-4,580-4,786Group1,7432834235488432,0972353855078601,9872,1542,317Adj. EBIT margin, %Americas40.0%40.1%37.3%41.4%33.3%38.0%34.9%34.8%39.8%37.3%36.8%37.1%37.3%EMEA33.9%32.3%32.3%35.6%39.9%35.5%37.1%36.8%36.4%40.1%37.8%38.1%38.3%APAC33.4%35.0%36.1%33.3%38.2%35.7%35.4%36.2%35.1%38.3%36.4%36.7%36.9%Group10.3%7.4%9.7%11.7%16.3%11.6%6.4%9.4%11.6%16.8%11.5%11.9%12.2%",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "2c27d4007ee8c130",
      "text": "Source: Company disclosure (historical), Barclays Research estimates",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "10eed95403f1ec1c",
      "text": "FIGURE 2. Elekta: Barclays vs. pre Q1 2024/25 consensus estimates",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "b0d42abd4bb97bd0",
      "text": "Barclays estimatesConsensus estimatesΔQ2 25/26E25/26E26/27E27/28EQ2 25/26E25/26E26/26E27/28EQ2 25/26E2526/27E26/27E27/28EQ2 25/26E25/26E26/27E27/28E(in SEKm, Apr Y/E)Net sales4,09217,22618,02818,9164,27517,62318,57719,525-4.3%-2.3%-3.0%-3.1%Change with constant exchange rates0.4%2.5%4.9%4.9%4.7%4.3%5.6%5.2%-4.3ppt-1.8ppt-0.7ppt-0.2pptGross income adjusted1,4956,5286,8617,2381,5706,6477,0417,446-4.8%-1.8%-2.6%-2.8%Margin36.5%37.9%38.1%38.3%36.7%37.7%37.9%38.1%-0.2ppt0.2ppt0.2ppt0.1pptEBITDA adjusted7373,3733,5903,8027653,4123,6933,931-3.7%-1.1%-2.8%-3.3%Margin18.0%19.6%19.9%20.1%17.9%19.4%19.9%20.1%0.1ppt0.2ppt0.0ppt-0.0pptEBIT adjusted3851,9872,1542,3174472,0692,2762,488-13.9%-4.0%-5.4%-6.9%Margin9.4%11.5%11.9%12.2%10.5%11.7%12.2%12.7%-1.1ppt-0.2ppt-0.3ppt-0.5pptEBIT reported3851,9712,1542,3174462,0562,2752,487-13.7%-4.1%-5.3%-6.8%Income after financial items reported2951,6171,8041,9773631,7141,9692,204-18.7%-5.7%-8.4%-10.3%Net income reported2321,2631,4071,5422811,3261,5241,705-17.7%-4.8%-7.6%-9.6%EPS adjusted (basic)0.603.333.684.030.743.503.994.46-19.1%-4.7%-7.9%-9.7%EPS, reported0.603.303.684.030.743.473.994.46-18.8%-4.9%-7.8%-9.7%",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "5cd15826ba073db3",
      "text": "Source: Infront consensus (published on August 22, 2025), Barclays Research estimates",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "93f7952973faa4fc",
      "text": "- Q2 guidance: Expect pressure in Q2 on revenues from China and the US. See a recovery of growth in China in H2. Assume same level of gross margin impact from tariff as in Q1 throughout the year. Q1 tariff impact on an absolute basis was SEK 33 million. FX headwind should gradually improve in coming quarters. Do not expect organic growth in Q2 due to China and the US.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "32ba5a57e767f399",
      "text": "- Evo FDA approval: Continue to work with the FDA, timeline remains uncertain, cannot commit to approval before H2, although hope this to be the case. Potentially some market weakness from tariff as well that impacted volumes. Evo approval this year is assumed in the guide, although management note there are other geographic growth drivers that underpin guidance and they believe they can meet guidance without approval.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "18c3bf7de1114932",
      "text": "- EMEA: Growth is being led by software and Elekta Evo. Strong order development in EMEA.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "1ce49b3b53313620",
      "text": "- China: Did a lot of installations during anti-corruption measures in China whilst orders slowed. Order book is now at a low level, and remains below pre-pandemic levels, although now seeing a clear pick up in orders, which is expected to continue. Book-to-bill does remain well above 1. Comparison base also becomes easier. Expect sales to be down in Q2.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "2fc8e5ae94bcc1aa",
      "text": "- India: Quarters can be lumpy; see it as temporary weakness in an overall positive market. Below 1 LINAC per million in India versus 12 in the US.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "03254f971c90e92a",
      "text": "- Continued strong momentum in Europe supported by product launches- Solutions increased by \\(1\\%\\) and Service grew by \\(4\\%\\) - supported by software growth",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "e254a51bb84f8e59",
      "text": "- Negative FX impact and tariff costs- Price improvements",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "2d71c9b8b66663c1",
      "text": "- Lower gross margin- Increased net R&D expenses- Reduced selling and administrative expenses",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "93036c52703a1881",
      "text": "- Gross margin decline to \\(37\\%\\) (37.8%) with pressure from FX (-100 bps) and tariff costs (-90 bps).- Price increases and contribution from product launches continued in the quarter- Selling and admin expenses declined YoY by \\(4\\%\\) and \\(3\\%\\) , respectively, following previously implemented cost-savings activities- Net R&D expenses - increased by \\(17\\%\\) YoY. Higher amortizations and lower capitalization",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "cd2ec1c4c59b2d44",
      "text": "- Negative FX impact on net sales driven by stronger SEK vs main revenue currencies USD and EUR- Further margin pressure from USD depreciation vs main cost currencies EUR and GBP",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "dab84371b76fcb4d",
      "text": "- Unity: Elekta Unity's capability to treat prostate cancer while preserving erectile function gained significant attention- University of Texas Southwestern: Concluded a comprehensive deal including some of Elekta's most advanced solutions to the University of Texas Southwestern- FDA clearance: Leksell Gamma Knife received FDA clearance for treating a certain type of epilepsy. An important step towards expanding the scope of stereotactic radiosurgery",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "fb5ae07fc6e24c66",
      "text": "- Lower volumes in China and India- Chinese sales were negatively impacted by last year's weak order intake",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "0f51067ecceaf128",
      "text": "- Continued strong momentum in Europe supported by new product launches",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "8c151e0336dcceb3",
      "text": "FIGURE 3. Current vs. prior estimates deviation",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "1f15703df7e35cce",
      "text": "NewOldΔ(in SEKm, Apr Y/E)25/26E26/27E27/28E25/26E26/27E27/28E25/26E26/27E27/28ENet sales17,22618,02818,91617,19117,98718,8770.2%0.2%0.2%ccy sales growth, %2.5%4.9%4.9%3.3%4.9%4.9%-0.8pp-0.0pp-0.0ppAmericas0.4%3.9%4.1%0.2%3.9%4.1%0.2ppt0.0ppt0.0pptEMEA5.6%4.6%4.6%4.0%4.6%4.6%1.6ppt-0.0ppt-0.0pptAPAC0.9%6.0%6.0%5.0%6.0%6.0%-4.1ppt-0.0ppt-0.0pptGross income adjusted6,5286,8617,2386,4926,8367,2020.6%0.4%0.5%Margin37.9%38.1%38.3%37.8%38.0%38.2%0.1ppt0.1ppt0.1pptEBITDA adjusted3,3733,5903,8023,3163,5293,7431.7%1.7%1.6%Margin19.6%19.9%20.1%19.3%19.6%19.8%0.3ppt0.3ppt0.3pptEBIT adjusted1,9872,1542,3172,0202,1852,350-1.6%-1.4%-1.4%Margin11.5%11.9%12.2%11.8%12.1%12.4%-0.2ppt-0.2ppt-0.2pptEBIT1,9712,1542,3172,0202,1852,350-2.4%-1.4%-1.4%Financial items-355-350-340-318-314-30611.4%11.3%11.1%Income tax-354-397-435-373-412-450-5.2%-3.6%-3.3%Net income adjusted1,2751,4071,5421,3291,4591,594-4.0%-3.6%-3.3%EPS adjusted (basic)3.333.684.033.473.814.16-3.9%-3.5%-3.2%",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "5f7671437c015f95",
      "text": "Source: Barclays Research estimates",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "ee6a0112094855b8",
      "text": "FIGURE 4. EKTAB: Absolute F1 P/E valuation",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "6ba6cb02fb1c16b9",
      "text": "Source: Bloomberg; Barclays Research",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "e2dbafffa39eaa58",
      "text": "FIGURE 5. EKTAB: Absolute F1 EV/EBITDA valuation",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "da2b19ce1b32a9de",
      "text": "Source: Bloomberg; Barclays Research",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "2275b196415cf3b0",
      "text": "FIGURE 6. EKTAB: Relative F1 P/E valuation to EU Medtech index",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "6099cf0496f36ded",
      "text": "Source: Bloomberg; Barclays Research",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "4f4ccbd2fdff555e",
      "text": "FIGURE 7. EKTAB: Relative F1 EV/EBITDA valuation to EU Medtech index",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "31f1c112c0a071b6",
      "text": "Source: Bloomberg; Barclays Research",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "1a2301e5ec2101da",
      "text": "FIGURE 8. 2025E P/E (x)",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "9c3fbe102c85df58",
      "text": "FIGURE 9. 2025E EV/EBITDA (x)",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "72ed3f5dcf7a71e3",
      "text": "\\*indicates covered by Barclays and for other BBG consensus were used. Data calendarisedSource: Bloomberg, Barclays Research",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "c35697f49201e01f",
      "text": "\\*indicates covered by Barclays and for other BBG consensus were used. Data calendarisedSource: Bloomberg, Barclays Research",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "7985f0b73d88d5dd",
      "text": "FIGURE 10. European MedTech & Services: P/E vs. EPS CAGR",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "a9b0b933bccbb6a2",
      "text": "Data calendaredSource: Bloomberg, Barclays Research. \\*indicates companies covered by Barclays; for others Bloomberg consensus was used (pricing as of 28/08/2025)",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "5da8c2dfe6d13363",
      "text": "FIGURE 11. European MedTech & Services: EV/EBITDA vs. EBITDA CAGR",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "5d8e0c7760951c9e",
      "text": "Data calendaredSource: Bloomberg, Barclays Research. \\*indicates companies covered by Barclays; for others Bloomberg consensus was used (pricing as of 28/08/2025)",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "113665033c82b85c",
      "text": "FIGURE 12. Imaging and Advanced Therapies companies valuation comps",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "7d5cea094092f5aa",
      "text": "CompanyCCYRecMkt Cap (EUR m)Share price performance24-26 CAGRs (%)P/E (adj)EV/EBITDAND/EBITDADiv yield (%)PTPriceUpside (%)1mo (%)1yr (%)SalesEBITDAEPS2025E2026E2025E2026E2025E2025EElekta*SEKUW1,61748.046.62.9-4.7-33.0-0.82.34.514.413.16.76.51.55.1Philips*EUROW22,73528.523.620.76.8-14.31.74.08.816.514.39.79.01.83.6Siemens Healthineers*EUROW53,43362.047.231.4-1.0-9.14.98.66.619.418.313.913.02.52.4Medtronic*USDOW100,732109.092.118.4-0.23.95.66.34.816.515.513.212.11.83.2Barco NVEUR1,32514.31.417.73.98.718.416.414.58.37.3-1.93.8Boston ScientificUSD133,713105.4-0.432.614.718.416.335.431.127.323.81.30.0CanonJPY33,8994,361.06.8-13.01.618.350.712.511.69.59.00.73.7Fisher &amp;amp; PaykelNZD10,85836.80.52.311.615.723.951.844.429.626.4-0.31.3GE HealthcareUSD28,73473.5-5.4-12.44.21.04.216.415.110.69.51.30.1HologicUSD12,57866.10.6-17.83.43.46.015.314.311.09.90.10.0AngioDynamics IncUSD34710.09.435.43.541.2-14.0NMNMNMNMNMNMMarket average399,9721.2-0.611.311.66.323.821.417.615.81.51.7",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "ccc5a0e22bdad992",
      "text": "s 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 2026E 2025E 2025E 2025E 2025E 2026E 2025E 2025E 2026E 2025E 202",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "36465b3916d92d67",
      "text": "FIGURE 13. EU MedTech & Services Valuation Sheet & Key Metrics",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "3b4c4bf88768e2c5",
      "text": "CompanyCCYRecMkt Cap (EUR m)Share price performance24-26 CAGRs (%)P/E (adj)EV/EBITDAND/EBITDADiv yield (%)PTPricePotenti al upside (%)1mo (%)1yr (%)SalesEBITDAEPS2025E2026E2025E2026E2025E2025EServicesAmplifon*EUROW3,54320.515.731.0-21.5-46.23.73.76.220.016.89.28.42.91.6Fresenius Medical Care*EUREW12,62350.543.316.7-3.623.81.06.516.411.810.46.76.32.73.4Fresenius SE*EUROW26,06750.546.68.410.740.14.46.111.813.412.010.09.22.82.2Oxford Nanopore*GBpOW2,085160187.2-14.5-11.957.728.9NMNMNMNMNM-0.20.0Spire Healthcare*GBpOW1,030269221.021.7-1.8-12.55.69.636.720.613.47.76.94.41.2Vimian*SEKEW1,50337.031.617.2-13.0-23.416.317.426.022.216.613.411.21.30.0Total Services46,850-6.86.68.67.216.213.311.68.78.02.62.3MedTechColoplast*DKKEW18,606740608.621.6-2.1-32.75.67.811.730.322.916.414.92.43.6Convatec*GBpOW5,526325233.439.2-2.30.46.18.813.317.816.111.810.81.62.3Demant*DKKEW6,960270.0243.011.1-12.7-13.64.11.81.420.718.411.810.72.5NMElekta*SEKUW1,61748.046.62.9-4.7-33.0-0.82.34.514.413.16.76.51.55.1GN Store Nord*DKKEW2,345139.0116.019.812.5-24.30.38.514.415.710.611.08.94.10.0Philips*EUROW22,73528.523.620.76.8-14.31.74.08.816.514.39.79.01.83.6Siemens Healthineers*EUROW53,43362.047.231.4-1.0-9.14.98.66.619.418.313.913.02.52.4Smith &amp; Nephew*GBpEW13,8891,3001,377.0-5.617.617.45.712.518.018.315.811.510.31.72.2Sonova*CHFUW14,726225.0231.1-2.6-0.7-20.94.55.92.922.020.514.313.51.01.9Straumann*CHFOW16,127133.094.640.5-12.9-23.78.59.19.330.125.318.315.8-0.11.0Carl ZiessEUR3,88443.4-14.1-33.05.813.47.723.819.211.19.61.01.6EssilorLuxotticaEUR121,993263.47.022.65.57.58.037.233.218.917.11.31.5Total MedTech281,840-0.6-13.74.37.58.928.325.015.814.41.62.0Total MedTech &amp; Services328,690-2.6-6.95.97.411.326.023.014.813.51.72.0",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "9762f5ad4f394bc6",
      "text": "denetstk  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  u  t  t  t  t  t  t  t  t",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "f1fec0932b8211fd",
      "text": "I, Hassan Al- Wakeel, CFA, hereby certify (1) that the views expressed in this research report accurately reflect my personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "f7c01502546522ad",
      "text": "Elekta AB (EKTAB.ST, 27- Aug- 2025, SEK 48.94), Underweight/Positive, J",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "6e925f455d208cb2",
      "text": "Siemens Healthineers AG (SHLG.DE, 27- Aug- 2025, EUR 47.19), Overweight/Positive, A/D/E/J/K/L/M/N",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "84dc2ff2348a976f",
      "text": "Unless otherwise indicated, prices are sourced from Bloomberg and reflect the closing price in the relevant trading market, which may not be the last available closing price at the time of publication.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "8b7f275b933cab3c",
      "text": "H: This issuer beneficially owns more than \\(5\\%\\) of any class of common equity securities of Barclays PLC.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "e5ceb1eed1e4ce59",
      "text": "P: A partner, director or officer of Barclays Capital Canada Inc. has, during the preceding 12 months, provided services to the subject company for remuneration, other than normal course investment advisory or trade execution services.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "8370f03fa4033fb2",
      "text": "R: Barclays Capital Canada Inc. has received compensation for investment banking services from this issuer in the past 12 months.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "3730182bc1e1f202",
      "text": "S: This issuer is a Corporate Broker to Barclays PLC.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "b17ef43a34a6f83e",
      "text": "U: The equity securities of this Canadian issuer include subordinate voting restricted shares.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "e664844a34205627",
      "text": "V: The equity securities of this Canadian issuer include non- voting restricted shares.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "5aa7e6598e067b84",
      "text": "Overweight - The stock is expected to outperform the unweighted expected total return of the industry coverage universe over a 12- month investment horizon.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "c746964a84d1fe1b",
      "text": "Equal Weight - The stock is expected to perform in line with the unweighted expected total return of the industry coverage universe over a 12- month investment horizon.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "c24e9f5f4806b825",
      "text": "Underweight - The stock is expected to underperform the unweighted expected total return of the industry coverage universe over a 12- month investment horizon.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "b59d4441f62a1e70",
      "text": "Positive - industry coverage universe fundamentals/valuations are improving.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "b3f74704795db256",
      "text": "Neutral - industry coverage universe fundamentals/valuations are steady, neither improving nor deteriorating.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "5dbecebb9b87462c",
      "text": "Negative - industry coverage universe fundamentals/valuations are deteriorating.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "38c035b79ffc4a0f",
      "text": "Below is the list of companies that constitute the \"industry coverage universe\":",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "11b036161c212ddb",
      "text": "Amplifon SpA (AMPF.MI)",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "65df4d9319249ce5",
      "text": "Demat A/S (DEMANT.CO)",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "f3d8383f9c9ff3e3",
      "text": "Fresenius SE & Co KGaA (FREG.DE)",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "bf9c8164a643c636",
      "text": "Oxford Nanopore Technologies PLC (ONT.L)",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "4a8c0bd5cdc3982f",
      "text": "Coloplast A/S (COLOb.CO) Elekta AB (EKTAb.ST) GN Store Nord A/S (GN.CO) Siemens Healthineers AG (SHLG.DE)",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "c99d99ab28d68c88",
      "text": "ConvaTec Group PLC (CTEC.L) Fresenius Medical Care AG (FMEG.DE) Koninklijke Philips N.V. (PHG.AS) Smith & Nephew plc (SN.L)",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "e66363cff1a6b6cd",
      "text": "Sonova Holding AG (SOON.S) Vimian Group AB (VIMIAN.ST)",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "036be93ee9dbb753",
      "text": "In addition to any ratings assigned under Barclays' formal rating systems, this publication may contain investment recommendations in the form of trade ideas, thematic screens, scorecards or portfolio recommendations that have been produced by analysts within Equity Research. Any such investment recommendations shall remain open until they are subsequently amended, rebalanced or closed in a future research report.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "0d831ffc4127015b",
      "text": "Barclays may also re- distribute equity research reports produced by third- party research providers that contain recommendations that differ from and/or conflict with those published by Barclays' Equity Research Department.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "eac12329102b2b76",
      "text": "Barclays Equity Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view all investment recommendations published by Barclays Equity Research in the preceding 12 months please refer to https://live.barcap.com/go/research/Recommendations.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "451845972641738a",
      "text": "Stock Rating: UNDERWEIGHT  Industry View: POSITIVE  Closing Price: SEK 48.94 (27-Aug-2025)",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "a8cfe95814c6d2b1",
      "text": "Rating and Price Target Chart - SEK (as of 27-Aug-2025)  Currency=SEK",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "14c979ecf3693d20",
      "text": "Source: IDC, Barclays Research",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "abbb603987851467",
      "text": "Link to Barclays Live for interactive charting",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "8fd1880dd0f6fad1",
      "text": "Publication DateClosing Price*RatingAdjusted Price Target29-May-202552.9549.5024-Feb-202560.2557.5028-Nov-202464.7064.5031-Oct-202466.7065.0006-Jun-202469.5063.0001-Mar-202473.5866.0001-Dec-202381.8068.0004-Oct-202375.92Underweight70.00",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "3bf9b6a1292b5f60",
      "text": "Source: Bloomberg, Barclays Research",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "4d5b68ee9fe2f00c",
      "text": "\\*This is the closing price referenced in the publication, which may not be the last available closing price at the time of publication.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "f333060defee1e56",
      "text": "Historical stock prices and price targets may have been adjusted for stock splits and dividends.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "5471e0e769f3b463",
      "text": "Valuation Methodology: We derive our PT for Elekta using a blend of c.12x PE and 8x EV/EBITDA on Apr'26E, or a c.30% discount to peers, which we see as justified given a poor track record of execution and downside risk to margins over the medium term. We sense check with DCF.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "7626c505bb87c6ae",
      "text": "Risks which May Impede the Achievement of the Barclays Research Valuation and Price Target: i) An improvement in the US market and some evidence of market share gains; ii) improved mix and margins; iii) significant traction in new product launches, particularly Unity.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "0748312252b7a85b",
      "text": "Stock Rating: OVERWEIGHT  Industry View: POSITIVE  Closing Price: EUR 47.19 (27-Aug-2025)",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "b6e4364d77ef0a14",
      "text": "Rating and Price Target Chart - EUR (as of 27-Aug-2025)  Currency= EUR",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "fcc2d1def18760bc",
      "text": "Source: IDC, Barclays Research  Link to Barclays Live for interactive charting",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "dbc756c27bbc0089",
      "text": "Publication DateClosing Price*RatingAdjusted Price Target31-Jul-202549.4962.0027-Jun-202546.8461.0008-May-202546.5862.0028-Mar-202550.6665.0007-Feb-202557.1466.0007-Nov-202451.2662.5001-Aug-202449.6360.5005-Mar-202455.7261.0004-Jan-202452.5058.0009-Nov-202348.5858.5025-Sep-202345.7460.0003-Aug-202352.2860.5021-Jun-202351.0862.0011-May-202353.3262.0003-Mar-202348.8163.0002-Feb-202353.6262.0009-Jan-202347.0863.0009-Nov-202248.8364.0003-Oct-202244.2862.00",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "ef60eda95f75a27a",
      "text": "On 28-Aug-2022, prior to any intra-day change that may have been published, the rating for this security was Overweight, and the adjusted price target was 64.00.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "0951038319daffaa",
      "text": "Source: Bloomberg, Barclays Research",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "0ee52827c92057c2",
      "text": "*This is the closing price referenced in the publication, which may not be the last available closing price at the time of publication.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "f368f0ed7f4433cb",
      "text": "Historical stock prices and price targets may have been adjusted for stock splits and dividends.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "4d8027a243f9d41f",
      "text": "**Valuation Methodology:** We derive our price target based on a blend of 2025E P/E (29x) and EV/EBITDA (16x) multiples, representing a c.8% premium to MedTech peers. We believe SHL is a high-quality name that warrants a premium, supported by its strong fundamentals and long-term growth prospects. We sense-check with DCF and SoTP, which yield similar results.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "01b311d22c377ff8",
      "text": "**Risks which May Impede the Achievement of the Barclays Research Valuation and Price Target:** Risks include the integration of the VAR deal,execution of the diagnostics turnaround, margin pressure, cuts to hospital capex as well as competition.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "f50e3e9f9f225235",
      "text": "Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this publication or its contents.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "b14bd817fccd366b",
      "text": "Other than disclosures relating to Barclays, the information contained in this publication has been obtained from sources that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Appearances by Third- Party Speakers: Any views or opinions expressed by third- party speakers during this event are solely those of the speaker and do not represent the views or opinions of Barclays. Barclays is not responsible for, and makes no warranties whatsoever as to, the information or opinions contained in any written, electronic, audio or video presentations by any third- party speakers at the event (\"Third- Party Content\"). Any such Third- Party Content has not been adopted or endorsed by Barclays and does not represent the views or opinions of Barclays. Third- Party Content is provided for information purposes only and has not been independently verified by Barclays for its accuracy or completeness.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "a3b7356689a7fbed",
      "text": "The views in this publication are solely and exclusively those of the authoring analyst(s) and are subject to change, and Barclays Research has no obligation to update its opinions or the information in this publication. Unless otherwise disclosed herein, the analysts who authored this report have not received any compensation from the subject companies in the past 12 months. If this publication contains recommendations, they are general recommendations that were prepared independently of any other interests, including those of Barclays and/or its affiliates, and/or the subject companies. This publication does not contain personal investment recommendations or investment advice or take into account the individual financial circumstances or investment objectives of the clients who receive it. Barclays is not a fiduciary to any recipient of this publication. The securities and other investments discussed herein may not be suitable for all investors and may not be available for purchase in all jurisdictions. The United States imposed sanctions on certain Chinese companies (https://home.treasury.gov/policy- issues/financial- sanctions/sanctions- programs- and- country- information/chinese- military- companies- sanctions), which may restrict U.S. persons from purchasing securities issued by those companies. Investors must independently evaluate the merits and risks of the investments discussed herein, including any sanctions restrictions that may apply, consult any independent advisors they believe necessary, and exercise independent judgment with regard to any investment decision. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results. The information provided does not constitute a financial benchmark and should not be used as a submission or contribution of input data for the purposes of determining a financial benchmark.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "c6c50d08d3f98d76",
      "text": "This publication is not investment company sales literature as defined by Section 270.24(b) of the US Investment Company Act of 1940, nor is it intended to constitute an offer, promotion or recommendation of, and should not be viewed as marketing (including, without limitation, for the purposes of the UK Alternative Investment Fund Managers Regulations 2013 (SI 2013/1773) or AIFMD (Directive 2011/61)) or pre- marketing (including, without limitation, for the purposes of Directive (EU) 2019/1160) of the securities, products or issuers that are the subject of this report.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "f430b84194412bc6",
      "text": "Third Party Distribution: Any views expressed in this communication are solely those of Barclays and have not been adopted or endorsed by any third party distributor.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "388e37e503a6f7d9",
      "text": "This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of Canadian Investment Regulatory Organization (www.circ.ca), and a Member of the Canadian Investor Protection Fund (CIPF).",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "8becb08709b287c1",
      "text": "This communication is directed at persons who are a \"Wholesale Client\" as defined by the Australian Corporations Act 2001.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "a821adb195cff577",
      "text": "Middle East: Nothing herein should be considered investment advice as defined in the Israeli Regulation of Investment Advisory, Investment Marketing and Portfolio Management Law, 1995 (\"Advisory Law\"). This document is being made to eligible clients (as defined under the Advisory Law) only. Barclays Israeli branch previously held an investment marketing license with the Israel Securities Authority but it cancelled such license on 30/11/2014 as it solely provides its services to eligible clients pursuant to available exemptions under the Advisory Law, therefore a license with the Israel Securities Authority is not required. Accordingly, Barclays does not maintain an insurance coverage pursuant to the Advisory Law.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "749b4dbd2b708db3",
      "text": "Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar: Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar. Related financial products or services are only available to Business Customers as defined by the Qatar Financial Centre Regulatory Authority.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "be27d2be6709a630",
      "text": "Russia: This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain information about or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus not eligible for non- Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of this material in your possession.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "c0b43765e8d93cd1",
      "text": "Sustainable Investing Related Research: There is currently no globally accepted framework or definition (legal, regulatory or otherwise) of, nor market consensus as to what constitutes a 'sustainable', 'ESG', 'green', 'climate- friendly' or an equivalent company, investment, strategy or consideration or what precise attributes are required to be eligible to be categorised by such terms. This means there are different ways to evaluate a company or an investment and so different values may be placed on certain sustainability credentials as well as adverse ESG- related impacts of companies and ESG controversies. The evolving nature of sustainable investing considerations, models and methodologies means it can be challenging to definitively and universally classify a company or investment under a sustainable investing label and there may be areas where such companies and investments could improve or where adverse ESG- related impacts or ESG controversies exist. The evolving nature of sustainable finance related regulations and the development of jurisdiction- specific regulatory criteria also means that there is likely to be a degree of divergence as to the interpretation of such terms in the market. We expect industry guidance, market practice, and regulations in this field to continue to evolve.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "f3eda6b81bfd25c8",
      "text": "Any information, data, image, or other content including from a third party source contained, referred to herein or used for whatsoever purpose by Barclays or a third party (\"Information\"), in relation to any actual or potential 'ESG', 'sustainable' or equivalent objective, issue, factor or consideration is not intended to be relied upon for ESG or sustainability classification, regulatory regime or industry initiative purposes (\"ESG Regimes\"), unless otherwise stated. Nothing in these materials, including any images included therein, is intended to convey, suggest or indicate that Barclays considers or represents any product, service, person or body mentioned in these materials as meeting or qualifying for any ESG or sustainability classification, label or similar standards that may exist under ESG Regimes. Barclays has not conducted any assessment of compliance with ESG Regimes. Parties are reminded to make their own assessments for these purposes.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "bff7cb045b6f2c26",
      "text": "IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax- related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.",
      "page": 19,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "8ecf5f701f73bde6",
      "name": "Adjusted Price",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8d671e4a1810b7de",
      "name": "Advanced Therapies",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d1cf412485ca8530",
      "name": "Advisory Law",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d86c021f43f2bc6f",
      "name": "AngioDynamics Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c1c8b162e639d05c",
      "name": "Apr Source",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "facedae141187a9f",
      "name": "Australian Corporations",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "46a2e39eafb9f3ae",
      "name": "Barclays Capital",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "64387d09d2494c79",
      "name": "Barclays Capital Canada Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4d2d57430a6b5e51",
      "name": "Barclays Equity",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d1d3bfaf58595d0a",
      "name": "Barclays Israeli",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "05ab2ec667d770bf",
      "name": "Barclays Live",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "520bb613ae942fa6",
      "name": "Barclays PLC",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ccf133d649c357ba",
      "name": "Barclays Research",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4f1e43d19f17b5c9",
      "name": "Barco NV",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "fc7e7271fb92a64e",
      "name": "Boston Scientific",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6e0ffcf69212414d",
      "name": "Business Customers",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "13eec11f9f77d58d",
      "name": "Canada Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7860a2554c61a53f",
      "name": "Canadian Investment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d704b6ac0c024d24",
      "name": "Canadian Investor",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "0dd1805c8fd47128",
      "name": "Care AG",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "da6ebbcdea35a3f3",
        "value": 0.047,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ew, with a stronger EBIT print marred by softer Q2 expectations, resulting in shares being down c.- 4.7% (vs. SXDP c.- 0.8%). No FDA approval for Evo yet, although management are hopefully this will b",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "529f0d95d96b98bc",
        "value": 0.008,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "EBIT print marred by softer Q2 expectations, resulting in shares being down c.- 4.7% (vs. SXDP c.- 0.8%). No FDA approval for Evo yet, although management are hopefully this will be a H1 event. We upd",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b24ed64f1838224e",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "by a beat on EBIT, with sales broadly in line supported entirely by momentum in EMEA, which grew c.+15% in ccy, driven by Evo (although we note an easy comparison base of - 12%). Management expects th",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "7e24af599d1d9855",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tum in EMEA, which grew c.+15% in ccy, driven by Evo (although we note an easy comparison base of - 12%). Management expects the US to continue to be a drag in Q2 though are hopeful of an FDA approval",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b069ac31adc0338c",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ewhere, China order momentum is improving with a sales recovery expected in H2. Overall, we make 1- 2% FY EBIT cuts and lower our expectations for Q2 following management commentary around softer US a",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b22299ed019c2930",
        "value": 0.047,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "m management's presentation: 1) Q2 guidance: Organic growth is not expected in Q2 (versus consensus +4.7% ccy growth) given sales pressure stemming from both the US and China. On gross margin, a simil",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "c44097f8f6110883",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "**Valuation and estimates:** We make c.1-2% cuts to EBIT and c.3-4% cuts to EPS, partly driven by higher interest expense. As a result, we lowe",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "6f692a5e9ad4ccf9",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "**Valuation and estimates:** We make c.1-2% cuts to EBIT and c.3-4% cuts to EPS, partly driven by higher interest expense. As a result, we lower our PT to SEK 48 (from",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "a3c353ae8b275bbd",
        "value": 0.016,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "-2025)</td></tr><tr><td>Revenue</td><td>18,016</td><td>17,596</td><td>18,028</td><td>18,916</td><td>1.6%</td><td>Price Target</td></tr><tr><td>Gross profit</td><td>6,810</td><td>6,528</td><td>6,861</t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "89ecc5550db46023",
        "value": 0.021,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "arget</td></tr><tr><td>Gross profit</td><td>6,810</td><td>6,528</td><td>6,861</td><td>7,238</td><td>2.1%</td><td></td></tr><tr><td>EBITDA (adj)</td><td>396</td><td>3,498</td><td>3,590</td><td>3,802</t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "6dcc8f4619531eec",
        "value": 0.038,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td></tr><tr><td>EBITDA (adj)</td><td>396</td><td>3,498</td><td>3,590</td><td>3,802</td><td>3.8%</td><td></td></tr><tr><td>EBIT (adj)</td><td>1,097</td><td>1,987</td><td>2,154</td><td>2,317</t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "aa0dd6bf7c7c7d8c",
        "value": 0.034,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td></tr><tr><td>EBIT (adj)</td><td>1,097</td><td>1,987</td><td>2,154</td><td>2,317</td><td>3.4%</td><td></td></tr><tr><td>Pre-tax income (adj)</td><td>1,697</td><td>1,633</td><td>1,804</td><t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "b226d436dd7ed4fc",
        "value": 0.052000000000000005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>Pre-tax income (adj)</td><td>1,697</td><td>1,633</td><td>1,804</td><td>1,977</td><td>5.2%</td><td></td></tr><tr><td>Net income (adj)</td><td>1,182</td><td>1,275</td><td>1,407</td><td>1,",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "349449ab2dc36945",
        "value": 0.09300000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></td></tr><tr><td>Net income (adj)</td><td>1,182</td><td>1,275</td><td>1,407</td><td>1,542</td><td>9.3%</td><td></td></tr><tr><td>EPS (adj) (SEK)</td><td>3.08</td><td>3.33</td><td>3.68</td><td>4.03</",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "acb68c38b7c12add",
        "value": 0.09300000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td></td></tr><tr><td>EPS (adj) (SEK)</td><td>3.08</td><td>3.33</td><td>3.68</td><td>4.03</td><td>9.3%</td><td></td></tr><tr><td>Diluted shares (mn)</td><td>382</td><td>382</td><td>382</td><td>382</",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "7cef5465c0b3800a",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td></td></tr><tr><td>Diluted shares (mn)</td><td>382</td><td>382</td><td>382</td><td>382</td><td>0.0%</td><td></td></tr><tr><td>DPS (SEK)</td><td>2.40</td><td>2.40</td><td>2.40</td><td>2.42</td><td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "28b9e7617523cb48",
        "value": 0.002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".0%</td><td></td></tr><tr><td>DPS (SEK)</td><td>2.40</td><td>2.40</td><td>2.40</td><td>2.42</td><td>0.2%</td><td></td></tr><tr><td>Margin and return data</td><td>2025A</td><td>2026E</td><td>2027E</td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "40db3a2b02acccfd",
        "value": 0.025,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>Cash flow from operations</td><td>2,626</td><td>2,075</td><td>2,667</td><td>2,827</td><td>2.5%</td><td></td></tr><tr><td>Capital expenditure</td><td>-1,570</td><td>-1,399</td><td>-1,382</td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "21ed604c5fba3a42",
        "value": 0.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr><tr><td>Equity free cash flow</td><td>708</td><td>868</td><td>1,231</td><td>1,417</td><td>26.0%</td><td></td></tr><tr><td>Tangible fixed assets</td><td>901</td><td>864</td><td>822</td><td>77",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "92aa2037eb9163c8",
        "value": -0.048,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td></td></tr><tr><td>Tangible fixed assets</td><td>901</td><td>864</td><td>822</td><td>778</td><td>-4.8%</td><td></td></tr><tr><td>Intangible fixed assets</td><td>11,917</td><td>12,357</td><td>12,580",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "6b4f4519d8646508",
        "value": 0.023,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>Intangible fixed assets</td><td>11,917</td><td>12,357</td><td>12,580</td><td>12,741</td><td>2.3%</td><td></td></tr><tr><td>Cash and equivalents</td><td>2,955</td><td>2,666</td><td>2,744</td><t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "81d09af6e3b9a320",
        "value": 0.005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>Cash and equivalents</td><td>2,955</td><td>2,666</td><td>2,744</td><td>2,997</td><td>0.5%</td><td></td></tr><tr><td>Total assets</td><td>28,977</td><td>29,493</td><td>30,058</td><td>30,",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "68ec62ca44f2923e",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></td></tr><tr><td>Total assets</td><td>28,977</td><td>29,493</td><td>30,058</td><td>30,767</td><td>2.0%</td><td></td></tr><tr><td>Short and long-term debt</td><td>6,373</td><td>6,576</td><td>6,576</t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "c5744fa3620d134f",
        "value": 0.011000000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>Short and long-term debt</td><td>6,373</td><td>6,576</td><td>6,576</td><td>6,576</td><td>1.1%</td><td></td></tr><tr><td>Other long-term liabilities</td><td>625</td><td>634</td><td>634</td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "d6d0ab0e844abd4e",
        "value": 0.005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>Other long-term liabilities</td><td>625</td><td>634</td><td>634</td><td>634</td><td>0.5%</td><td></td></tr><tr><td>Total liabilities</td><td>20,129</td><td>20,121</td><td>20,196</td><t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "d09540402f0bf271",
        "value": 0.002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>Total liabilities</td><td>20,129</td><td>20,121</td><td>20,196</td><td>20,280</td><td>0.2%</td><td></td></tr><tr><td>Total invested capital</td><td>15,221</td><td>15,948</td><td>16,438</",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "96a995d63e2752d1",
        "value": 0.039,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>Total invested capital</td><td>15,221</td><td>15,948</td><td>16,438</td><td>17,063</td><td>3.9%</td><td></td></tr><tr><td>Net debt/(funds)</td><td>4,612</td><td>5,073</td><td>4,995</td><td>4,",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "87d622a2f6dd6c43",
        "value": 0.009000000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></td></tr><tr><td>Net debt/(funds)</td><td>4,612</td><td>5,073</td><td>4,995</td><td>4,742</td><td>0.9%</td><td></td></tr><tr><td>Minorities</td><td>45</td><td>46</td><td>46</td><td>46</td><td>0.7%</",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "f17c2cf0a6c8572c",
        "value": 0.006999999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>0.9%</td><td></td></tr><tr><td>Minorities</td><td>45</td><td>46</td><td>46</td><td>46</td><td>0.7%</td><td></td></tr><tr><td>Shareholders&#x27; equity</td><td>8,803</td><td>9,326</td><td>9,816</",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "3d71397e84fe4d22",
        "value": 0.059000000000000004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>Shareholders&#x27; equity</td><td>8,803</td><td>9,326</td><td>9,816</td><td>10,441</td><td>5.9%</td><td></td></tr><tr><td>Valuation and leverage metrics</td><td>2025A</td><td>2026E</td><td>20",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "d3cbd9c07a0d5d77",
        "value": 0.381,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "21</td><td>2,062</td><td>6,528</td><td>6,861</td><td>7,238</td><td></td></tr><tr><td>Margin</td><td>38.1%</td><td>37.8%</td><td>35.7%</td><td>37.1%</td><td>40.2%</td><td>37.8%</td><td>37.0%</td><td>36",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "abd8cd1c3a6cb754",
        "value": 0.37799999999999995,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "62</td><td>6,528</td><td>6,861</td><td>7,238</td><td></td></tr><tr><td>Margin</td><td>38.1%</td><td>37.8%</td><td>35.7%</td><td>37.1%</td><td>40.2%</td><td>37.8%</td><td>37.0%</td><td>36.5%</td><td>37",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "d44e09fa9e3099be",
        "value": 0.35700000000000004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "28</td><td>6,861</td><td>7,238</td><td></td></tr><tr><td>Margin</td><td>38.1%</td><td>37.8%</td><td>35.7%</td><td>37.1%</td><td>40.2%</td><td>37.8%</td><td>37.0%</td><td>36.5%</td><td>37.2%</td><td>40",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "cc8ecc40dc5aaa37",
        "value": 0.371,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "61</td><td>7,238</td><td></td></tr><tr><td>Margin</td><td>38.1%</td><td>37.8%</td><td>35.7%</td><td>37.1%</td><td>40.2%</td><td>37.8%</td><td>37.0%</td><td>36.5%</td><td>37.2%</td><td>40.2%</td><td>37",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "602facd33fe6261d",
        "value": 0.402,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "38</td><td></td></tr><tr><td>Margin</td><td>38.1%</td><td>37.8%</td><td>35.7%</td><td>37.1%</td><td>40.2%</td><td>37.8%</td><td>37.0%</td><td>36.5%</td><td>37.2%</td><td>40.2%</td><td>37.9%</td><td>38",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "046d54e69601c8a9",
        "value": 0.37799999999999995,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>Margin</td><td>38.1%</td><td>37.8%</td><td>35.7%</td><td>37.1%</td><td>40.2%</td><td>37.8%</td><td>37.0%</td><td>36.5%</td><td>37.2%</td><td>40.2%</td><td>37.9%</td><td>38.1%</td><td>38",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "cfca8384a0eca811",
        "value": 0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Margin</td><td>38.1%</td><td>37.8%</td><td>35.7%</td><td>37.1%</td><td>40.2%</td><td>37.8%</td><td>37.0%</td><td>36.5%</td><td>37.2%</td><td>40.2%</td><td>37.9%</td><td>38.1%</td><td>38.3%</td><td></",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "e382307728b53ddf",
        "value": 0.365,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>38.1%</td><td>37.8%</td><td>35.7%</td><td>37.1%</td><td>40.2%</td><td>37.8%</td><td>37.0%</td><td>36.5%</td><td>37.2%</td><td>40.2%</td><td>37.9%</td><td>38.1%</td><td>38.3%</td><td></td></tr><tr><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "8b04dbb02c3fca9a",
        "value": 0.37200000000000005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>37.8%</td><td>35.7%</td><td>37.1%</td><td>40.2%</td><td>37.8%</td><td>37.0%</td><td>36.5%</td><td>37.2%</td><td>40.2%</td><td>37.9%</td><td>38.1%</td><td>38.3%</td><td></td></tr><tr><td>EBITDA adjus",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c13ab678953bd889",
        "value": 0.402,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>35.7%</td><td>37.1%</td><td>40.2%</td><td>37.8%</td><td>37.0%</td><td>36.5%</td><td>37.2%</td><td>40.2%</td><td>37.9%</td><td>38.1%</td><td>38.3%</td><td></td></tr><tr><td>EBITDA adjusted</td><td>2,",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "292cf98f66c67649",
        "value": 0.379,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>37.1%</td><td>40.2%</td><td>37.8%</td><td>37.0%</td><td>36.5%</td><td>37.2%</td><td>40.2%</td><td>37.9%</td><td>38.1%</td><td>38.3%</td><td></td></tr><tr><td>EBITDA adjusted</td><td>2,908</td><td>60",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "38ec8321fa0eaae1",
        "value": 0.381,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>40.2%</td><td>37.8%</td><td>37.0%</td><td>36.5%</td><td>37.2%</td><td>40.2%</td><td>37.9%</td><td>38.1%</td><td>38.3%</td><td></td></tr><tr><td>EBITDA adjusted</td><td>2,908</td><td>600</td><td>745<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "95973ba115bfb03a",
        "value": 0.38299999999999995,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>37.8%</td><td>37.0%</td><td>36.5%</td><td>37.2%</td><td>40.2%</td><td>37.9%</td><td>38.1%</td><td>38.3%</td><td></td></tr><tr><td>EBITDA adjusted</td><td>2,908</td><td>600</td><td>745</td><td>886</t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "2b20eaeb534ff2e1",
        "value": 0.172,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "65</td><td>1,222</td><td>3,373</td><td>3,590</td><td>3,802</td><td></td></tr><tr><td>Margin</td><td>17.2%</td><td>15.7%</td><td>17.2%</td><td>18.9%</td><td>22.6%</td><td>18.8%</td><td>15.0%</td><td>18",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c900ef27ae2a3469",
        "value": 0.157,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "22</td><td>3,373</td><td>3,590</td><td>3,802</td><td></td></tr><tr><td>Margin</td><td>17.2%</td><td>15.7%</td><td>17.2%</td><td>18.9%</td><td>22.6%</td><td>18.8%</td><td>15.0%</td><td>18.0%</td><td>19",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "721ceea525a1596f",
        "value": 0.172,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "73</td><td>3,590</td><td>3,802</td><td></td></tr><tr><td>Margin</td><td>17.2%</td><td>15.7%</td><td>17.2%</td><td>18.9%</td><td>22.6%</td><td>18.8%</td><td>15.0%</td><td>18.0%</td><td>19.8%</td><td>23",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "aef2f2363ee81137",
        "value": 0.18899999999999997,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "90</td><td>3,802</td><td></td></tr><tr><td>Margin</td><td>17.2%</td><td>15.7%</td><td>17.2%</td><td>18.9%</td><td>22.6%</td><td>18.8%</td><td>15.0%</td><td>18.0%</td><td>19.8%</td><td>23.8%</td><td>19",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "a6a1cecf3d28b217",
        "value": 0.226,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "02</td><td></td></tr><tr><td>Margin</td><td>17.2%</td><td>15.7%</td><td>17.2%</td><td>18.9%</td><td>22.6%</td><td>18.8%</td><td>15.0%</td><td>18.0%</td><td>19.8%</td><td>23.8%</td><td>19.6%</td><td>19",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "06cc3314146ffc58",
        "value": 0.188,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>Margin</td><td>17.2%</td><td>15.7%</td><td>17.2%</td><td>18.9%</td><td>22.6%</td><td>18.8%</td><td>15.0%</td><td>18.0%</td><td>19.8%</td><td>23.8%</td><td>19.6%</td><td>19.9%</td><td>20",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "6ba4395048724928",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Margin</td><td>17.2%</td><td>15.7%</td><td>17.2%</td><td>18.9%</td><td>22.6%</td><td>18.8%</td><td>15.0%</td><td>18.0%</td><td>19.8%</td><td>23.8%</td><td>19.6%</td><td>19.9%</td><td>20.1%</td><td></",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "5b5f01d3cd1dedc5",
        "value": 0.18,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>17.2%</td><td>15.7%</td><td>17.2%</td><td>18.9%</td><td>22.6%</td><td>18.8%</td><td>15.0%</td><td>18.0%</td><td>19.8%</td><td>23.8%</td><td>19.6%</td><td>19.9%</td><td>20.1%</td><td></td></tr><tr><t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "9094f09aff0e95a1",
        "value": 0.198,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>15.7%</td><td>17.2%</td><td>18.9%</td><td>22.6%</td><td>18.8%</td><td>15.0%</td><td>18.0%</td><td>19.8%</td><td>23.8%</td><td>19.6%</td><td>19.9%</td><td>20.1%</td><td></td></tr><tr><td>EBIT adjuste",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "5df4d1db1ea8c375",
        "value": 0.23800000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>17.2%</td><td>18.9%</td><td>22.6%</td><td>18.8%</td><td>15.0%</td><td>18.0%</td><td>19.8%</td><td>23.8%</td><td>19.6%</td><td>19.9%</td><td>20.1%</td><td></td></tr><tr><td>EBIT adjusted</td><td>1,74",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "a2eaac136c65e64c",
        "value": 0.196,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>18.9%</td><td>22.6%</td><td>18.8%</td><td>15.0%</td><td>18.0%</td><td>19.8%</td><td>23.8%</td><td>19.6%</td><td>19.9%</td><td>20.1%</td><td></td></tr><tr><td>EBIT adjusted</td><td>1,743</td><td>283<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "cbbfb88d6c9cff38",
        "value": 0.19899999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>22.6%</td><td>18.8%</td><td>15.0%</td><td>18.0%</td><td>19.8%</td><td>23.8%</td><td>19.6%</td><td>19.9%</td><td>20.1%</td><td></td></tr><tr><td>EBIT adjusted</td><td>1,743</td><td>283</td><td>423</t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "3433da60b753694e",
        "value": 0.201,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>18.8%</td><td>15.0%</td><td>18.0%</td><td>19.8%</td><td>23.8%</td><td>19.6%</td><td>19.9%</td><td>20.1%</td><td></td></tr><tr><td>EBIT adjusted</td><td>1,743</td><td>283</td><td>423</td><td>548</td>",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "e773f362e7d42efb",
        "value": 0.10300000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">507</td><td>860</td><td>1,987</td><td>2,154</td><td>2,317</td><td></td></tr><tr><td>Margin</td><td>10.3%</td><td>7.4%</td><td>9.7%</td><td>11.7%</td><td>16.3%</td><td>11.6%</td><td>6.4%</td><td>9.4%<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "edc9d448a3e1d7ff",
        "value": 0.07400000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "60</td><td>1,987</td><td>2,154</td><td>2,317</td><td></td></tr><tr><td>Margin</td><td>10.3%</td><td>7.4%</td><td>9.7%</td><td>11.7%</td><td>16.3%</td><td>11.6%</td><td>6.4%</td><td>9.4%</td><td>11.6%<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "455dc27b642b5068",
        "value": 0.09699999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "987</td><td>2,154</td><td>2,317</td><td></td></tr><tr><td>Margin</td><td>10.3%</td><td>7.4%</td><td>9.7%</td><td>11.7%</td><td>16.3%</td><td>11.6%</td><td>6.4%</td><td>9.4%</td><td>11.6%</td><td>16.8%",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "ae2abae923ddaeb9",
        "value": 0.11699999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ",154</td><td>2,317</td><td></td></tr><tr><td>Margin</td><td>10.3%</td><td>7.4%</td><td>9.7%</td><td>11.7%</td><td>16.3%</td><td>11.6%</td><td>6.4%</td><td>9.4%</td><td>11.6%</td><td>16.8%</td><td>11.5",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "cccf4cd61ecf8f5c",
        "value": 0.163,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ",317</td><td></td></tr><tr><td>Margin</td><td>10.3%</td><td>7.4%</td><td>9.7%</td><td>11.7%</td><td>16.3%</td><td>11.6%</td><td>6.4%</td><td>9.4%</td><td>11.6%</td><td>16.8%</td><td>11.5%</td><td>11.9",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "3c513f123e68d200",
        "value": 0.11599999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td></tr><tr><td>Margin</td><td>10.3%</td><td>7.4%</td><td>9.7%</td><td>11.7%</td><td>16.3%</td><td>11.6%</td><td>6.4%</td><td>9.4%</td><td>11.6%</td><td>16.8%</td><td>11.5%</td><td>11.9%</td><td>12.2",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "74b8634aac3773f6",
        "value": 0.064,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>Margin</td><td>10.3%</td><td>7.4%</td><td>9.7%</td><td>11.7%</td><td>16.3%</td><td>11.6%</td><td>6.4%</td><td>9.4%</td><td>11.6%</td><td>16.8%</td><td>11.5%</td><td>11.9%</td><td>12.2%</td><td></td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c735466dd4a47052",
        "value": 0.094,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>10.3%</td><td>7.4%</td><td>9.7%</td><td>11.7%</td><td>16.3%</td><td>11.6%</td><td>6.4%</td><td>9.4%</td><td>11.6%</td><td>16.8%</td><td>11.5%</td><td>11.9%</td><td>12.2%</td><td></td></tr><tr><td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "9e4f4a9d5b6498c9",
        "value": 0.11599999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>7.4%</td><td>9.7%</td><td>11.7%</td><td>16.3%</td><td>11.6%</td><td>6.4%</td><td>9.4%</td><td>11.6%</td><td>16.8%</td><td>11.5%</td><td>11.9%</td><td>12.2%</td><td></td></tr><tr><td>Adj. net inc",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "fcbcddcf4a6b7532",
        "value": 0.168,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>9.7%</td><td>11.7%</td><td>16.3%</td><td>11.6%</td><td>6.4%</td><td>9.4%</td><td>11.6%</td><td>16.8%</td><td>11.5%</td><td>11.9%</td><td>12.2%</td><td></td></tr><tr><td>Adj. net income</td><td>1,",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "6cb8d1908160e85e",
        "value": 0.115,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>11.7%</td><td>16.3%</td><td>11.6%</td><td>6.4%</td><td>9.4%</td><td>11.6%</td><td>16.8%</td><td>11.5%</td><td>11.9%</td><td>12.2%</td><td></td></tr><tr><td>Adj. net income</td><td>1,187</td><td>15",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "a6bd2b9c7f89117e",
        "value": 0.11900000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>16.3%</td><td>11.6%</td><td>6.4%</td><td>9.4%</td><td>11.6%</td><td>16.8%</td><td>11.5%</td><td>11.9%</td><td>12.2%</td><td></td></tr><tr><td>Adj. net income</td><td>1,187</td><td>155</td><td>243<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "20d9c03aee730fda",
        "value": 0.122,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>11.6%</td><td>6.4%</td><td>9.4%</td><td>11.6%</td><td>16.8%</td><td>11.5%</td><td>11.9%</td><td>12.2%</td><td></td></tr><tr><td>Adj. net income</td><td>1,187</td><td>155</td><td>243</td><td>353</t",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "91c1d291cde0e51f",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Americas</td><td>5.0%</td><td>16.0%</td><td>-8.0%</td><td>-5.0%</td><td>-6.0%</td><td>-2.0%</td><td>-4.0%</td><td>-3.",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "51ebb53e78033bc8",
        "value": 0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Americas</td><td>5.0%</td><td>16.0%</td><td>-8.0%</td><td>-5.0%</td><td>-6.0%</td><td>-2.0%</td><td>-4.0%</td><td>-3.4%</td><td>3.",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c650df4229517f80",
        "value": -0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td><td></td><td></td><td></td><td></td></tr><tr><td>Americas</td><td>5.0%</td><td>16.0%</td><td>-8.0%</td><td>-5.0%</td><td>-6.0%</td><td>-2.0%</td><td>-4.0%</td><td>-3.4%</td><td>3.2%</td><td>4.9",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "3f849cc7e0701710",
        "value": -0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td></td><td></td><td></td></tr><tr><td>Americas</td><td>5.0%</td><td>16.0%</td><td>-8.0%</td><td>-5.0%</td><td>-6.0%</td><td>-2.0%</td><td>-4.0%</td><td>-3.4%</td><td>3.2%</td><td>4.9%</td><td>0.4%",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "723d05dd4fe216b4",
        "value": -0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></td><td></td></tr><tr><td>Americas</td><td>5.0%</td><td>16.0%</td><td>-8.0%</td><td>-5.0%</td><td>-6.0%</td><td>-2.0%</td><td>-4.0%</td><td>-3.4%</td><td>3.2%</td><td>4.9%</td><td>0.4%</td><td>3.9%<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "caa389f3189e6e73",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>Americas</td><td>5.0%</td><td>16.0%</td><td>-8.0%</td><td>-5.0%</td><td>-6.0%</td><td>-2.0%</td><td>-4.0%</td><td>-3.4%</td><td>3.2%</td><td>4.9%</td><td>0.4%</td><td>3.9%</td><td>4.1%</",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "8d311b056b9d68cb",
        "value": -0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Americas</td><td>5.0%</td><td>16.0%</td><td>-8.0%</td><td>-5.0%</td><td>-6.0%</td><td>-2.0%</td><td>-4.0%</td><td>-3.4%</td><td>3.2%</td><td>4.9%</td><td>0.4%</td><td>3.9%</td><td>4.1%</td><td></td></",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "d6b3239940c9f9a1",
        "value": -0.034,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>5.0%</td><td>16.0%</td><td>-8.0%</td><td>-5.0%</td><td>-6.0%</td><td>-2.0%</td><td>-4.0%</td><td>-3.4%</td><td>3.2%</td><td>4.9%</td><td>0.4%</td><td>3.9%</td><td>4.1%</td><td></td></tr><tr><td>EME",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "8c6cf966eb4bca08",
        "value": 0.032,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>16.0%</td><td>-8.0%</td><td>-5.0%</td><td>-6.0%</td><td>-2.0%</td><td>-4.0%</td><td>-3.4%</td><td>3.2%</td><td>4.9%</td><td>0.4%</td><td>3.9%</td><td>4.1%</td><td></td></tr><tr><td>EMEA</td><td>3.0%",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "c72bb4cfc0317309",
        "value": 0.049,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-8.0%</td><td>-5.0%</td><td>-6.0%</td><td>-2.0%</td><td>-4.0%</td><td>-3.4%</td><td>3.2%</td><td>4.9%</td><td>0.4%</td><td>3.9%</td><td>4.1%</td><td></td></tr><tr><td>EMEA</td><td>3.0%</td><td>-12.",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "8fef8b13e6f573e3",
        "value": 0.004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>-5.0%</td><td>-6.0%</td><td>-2.0%</td><td>-4.0%</td><td>-3.4%</td><td>3.2%</td><td>4.9%</td><td>0.4%</td><td>3.9%</td><td>4.1%</td><td></td></tr><tr><td>EMEA</td><td>3.0%</td><td>-12.0%</td><td>-5",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "8f4bdadfd24b0193",
        "value": 0.37799999999999995,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ") and Service grew by \\(4\\%\\) - supported by software growth ## - Adj. gross margin of \\(37.0\\%\\) (37.8%) - Negative FX impact and tariff costs- Price improvements ## - Adj. EBIT margin of \\(6.5\\%\\) (",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "a4a95da45beed70a",
        "value": 0.07400000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "8%) - Negative FX impact and tariff costs- Price improvements ## - Adj. EBIT margin of \\(6.5\\%\\) (7.4%) - Lower gross margin- Increased net R&D expenses- Reduced selling and administrative expenses ##",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "a5b64f15fda6bfe6",
        "value": 0.37799999999999995,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ministrative expenses ## - EBIT margin bridge Q1 25 vs Q1 24: - Gross margin decline to \\(37\\%\\) (37.8%) with pressure from FX (-100 bps) and tariff costs (-90 bps).- Price increases and contribution ",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "db8f1c99612346c0",
        "value": 0.002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">17,226</td><td>18,028</td><td>18,916</td><td>17,191</td><td>17,987</td><td>18,877</td><td></td><td>0.2%</td><td>0.2%</td><td>0.2%</td></tr><tr><td>ccy sales growth, %</td><td>2.5%</td><td>4.9%</td><t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "f03d4ce4641641fc",
        "value": 0.002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>18,028</td><td>18,916</td><td>17,191</td><td>17,987</td><td>18,877</td><td></td><td>0.2%</td><td>0.2%</td><td>0.2%</td></tr><tr><td>ccy sales growth, %</td><td>2.5%</td><td>4.9%</td><td>4.9%</td><t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "9c4734c0fa7caabf",
        "value": 0.002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>18,916</td><td>17,191</td><td>17,987</td><td>18,877</td><td></td><td>0.2%</td><td>0.2%</td><td>0.2%</td></tr><tr><td>ccy sales growth, %</td><td>2.5%</td><td>4.9%</td><td>4.9%</td><td>3.3%</td><t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "15bb0281db418639",
        "value": 0.025,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "18,877</td><td></td><td>0.2%</td><td>0.2%</td><td>0.2%</td></tr><tr><td>ccy sales growth, %</td><td>2.5%</td><td>4.9%</td><td>4.9%</td><td>3.3%</td><td>4.9%</td><td>4.9%</td><td></td><td>-0.8pp</td><t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "83cea7decea8a037",
        "value": 0.049,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></td><td>0.2%</td><td>0.2%</td><td>0.2%</td></tr><tr><td>ccy sales growth, %</td><td>2.5%</td><td>4.9%</td><td>4.9%</td><td>3.3%</td><td>4.9%</td><td>4.9%</td><td></td><td>-0.8pp</td><td>-0.0pp</td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "e8c59bf6b9077e6a",
        "value": 0.049,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2%</td><td>0.2%</td><td>0.2%</td></tr><tr><td>ccy sales growth, %</td><td>2.5%</td><td>4.9%</td><td>4.9%</td><td>3.3%</td><td>4.9%</td><td>4.9%</td><td></td><td>-0.8pp</td><td>-0.0pp</td><td>-0.0pp</t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "e24af722cce4a3fc",
        "value": 0.033,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2%</td><td>0.2%</td></tr><tr><td>ccy sales growth, %</td><td>2.5%</td><td>4.9%</td><td>4.9%</td><td>3.3%</td><td>4.9%</td><td>4.9%</td><td></td><td>-0.8pp</td><td>-0.0pp</td><td>-0.0pp</td></tr><tr><t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "dff78d953e29cd93",
        "value": 0.049,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2%</td></tr><tr><td>ccy sales growth, %</td><td>2.5%</td><td>4.9%</td><td>4.9%</td><td>3.3%</td><td>4.9%</td><td>4.9%</td><td></td><td>-0.8pp</td><td>-0.0pp</td><td>-0.0pp</td></tr><tr><td>Americas</t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "7737605fd3aaaa3d",
        "value": 0.049,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>ccy sales growth, %</td><td>2.5%</td><td>4.9%</td><td>4.9%</td><td>3.3%</td><td>4.9%</td><td>4.9%</td><td></td><td>-0.8pp</td><td>-0.0pp</td><td>-0.0pp</td></tr><tr><td>Americas</td><td>0.4%</t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "36f9e952451d66d6",
        "value": 0.004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>4.9%</td><td></td><td>-0.8pp</td><td>-0.0pp</td><td>-0.0pp</td></tr><tr><td>Americas</td><td>0.4%</td><td>3.9%</td><td>4.1%</td><td>0.2%</td><td>3.9%</td><td>4.1%</td><td></td><td>0.2ppt</td><t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "31a7ff4cf7e0c967",
        "value": 0.039,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td>-0.8pp</td><td>-0.0pp</td><td>-0.0pp</td></tr><tr><td>Americas</td><td>0.4%</td><td>3.9%</td><td>4.1%</td><td>0.2%</td><td>3.9%</td><td>4.1%</td><td></td><td>0.2ppt</td><td>0.0ppt</td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "c2bcb27d057a3ac2",
        "value": 0.040999999999999995,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>-0.8pp</td><td>-0.0pp</td><td>-0.0pp</td></tr><tr><td>Americas</td><td>0.4%</td><td>3.9%</td><td>4.1%</td><td>0.2%</td><td>3.9%</td><td>4.1%</td><td></td><td>0.2ppt</td><td>0.0ppt</td><td>0.0ppt</t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "0fe356a114fe6071",
        "value": 0.002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>-0.0pp</td><td>-0.0pp</td></tr><tr><td>Americas</td><td>0.4%</td><td>3.9%</td><td>4.1%</td><td>0.2%</td><td>3.9%</td><td>4.1%</td><td></td><td>0.2ppt</td><td>0.0ppt</td><td>0.0ppt</td></tr><tr><t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "799eaa0d7cb47103",
        "value": 0.039,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-0.0pp</td></tr><tr><td>Americas</td><td>0.4%</td><td>3.9%</td><td>4.1%</td><td>0.2%</td><td>3.9%</td><td>4.1%</td><td></td><td>0.2ppt</td><td>0.0ppt</td><td>0.0ppt</td></tr><tr><td>EMEA</td><t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "88efc7a11078044e",
        "value": 0.040999999999999995,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr><tr><td>Americas</td><td>0.4%</td><td>3.9%</td><td>4.1%</td><td>0.2%</td><td>3.9%</td><td>4.1%</td><td></td><td>0.2ppt</td><td>0.0ppt</td><td>0.0ppt</td></tr><tr><td>EMEA</td><td>5.6%</td><t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "60cd0cb79beab51f",
        "value": 0.055999999999999994,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "9%</td><td>4.1%</td><td></td><td>0.2ppt</td><td>0.0ppt</td><td>0.0ppt</td></tr><tr><td>EMEA</td><td>5.6%</td><td>4.6%</td><td>4.6%</td><td>4.0%</td><td>4.6%</td><td>4.6%</td><td></td><td>1.6ppt</td><t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "4013d6ce3977eeec",
        "value": 0.046,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1%</td><td></td><td>0.2ppt</td><td>0.0ppt</td><td>0.0ppt</td></tr><tr><td>EMEA</td><td>5.6%</td><td>4.6%</td><td>4.6%</td><td>4.0%</td><td>4.6%</td><td>4.6%</td><td></td><td>1.6ppt</td><td>-0.0ppt</td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "70999a0d6454f9aa",
        "value": 0.046,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>0.2ppt</td><td>0.0ppt</td><td>0.0ppt</td></tr><tr><td>EMEA</td><td>5.6%</td><td>4.6%</td><td>4.6%</td><td>4.0%</td><td>4.6%</td><td>4.6%</td><td></td><td>1.6ppt</td><td>-0.0ppt</td><td>-0.0ppt<",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "d4dde23b579abd03",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>0.0ppt</td><td>0.0ppt</td></tr><tr><td>EMEA</td><td>5.6%</td><td>4.6%</td><td>4.6%</td><td>4.0%</td><td>4.6%</td><td>4.6%</td><td></td><td>1.6ppt</td><td>-0.0ppt</td><td>-0.0ppt</td></tr><tr>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "a40e59bb73690816",
        "value": 0.046,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "pt</td><td>0.0ppt</td></tr><tr><td>EMEA</td><td>5.6%</td><td>4.6%</td><td>4.6%</td><td>4.0%</td><td>4.6%</td><td>4.6%</td><td></td><td>1.6ppt</td><td>-0.0ppt</td><td>-0.0ppt</td></tr><tr><td>APAC</td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "66692a7343607b1d",
        "value": 0.046,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0ppt</td></tr><tr><td>EMEA</td><td>5.6%</td><td>4.6%</td><td>4.6%</td><td>4.0%</td><td>4.6%</td><td>4.6%</td><td></td><td>1.6ppt</td><td>-0.0ppt</td><td>-0.0ppt</td></tr><tr><td>APAC</td><td>0.9%</td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "db4340cb992730be",
        "value": 0.009000000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>4.6%</td><td></td><td>1.6ppt</td><td>-0.0ppt</td><td>-0.0ppt</td></tr><tr><td>APAC</td><td>0.9%</td><td>6.0%</td><td>6.0%</td><td>5.0%</td><td>6.0%</td><td>6.0%</td><td></td><td>-4.1ppt</td><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "ad116fe86eb6a9f6",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td></td><td>1.6ppt</td><td>-0.0ppt</td><td>-0.0ppt</td></tr><tr><td>APAC</td><td>0.9%</td><td>6.0%</td><td>6.0%</td><td>5.0%</td><td>6.0%</td><td>6.0%</td><td></td><td>-4.1ppt</td><td>-0.0ppt</t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "a6b6c30e24a60806",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>1.6ppt</td><td>-0.0ppt</td><td>-0.0ppt</td></tr><tr><td>APAC</td><td>0.9%</td><td>6.0%</td><td>6.0%</td><td>5.0%</td><td>6.0%</td><td>6.0%</td><td></td><td>-4.1ppt</td><td>-0.0ppt</td><td>-0.0ppt",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "fd8d171f15d2c811",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>-0.0ppt</td><td>-0.0ppt</td></tr><tr><td>APAC</td><td>0.9%</td><td>6.0%</td><td>6.0%</td><td>5.0%</td><td>6.0%</td><td>6.0%</td><td></td><td>-4.1ppt</td><td>-0.0ppt</td><td>-0.0ppt</td></tr><tr",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "7a57c0800030f1ea",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "t</td><td>-0.0ppt</td></tr><tr><td>APAC</td><td>0.9%</td><td>6.0%</td><td>6.0%</td><td>5.0%</td><td>6.0%</td><td>6.0%</td><td></td><td>-4.1ppt</td><td>-0.0ppt</td><td>-0.0ppt</td></tr><tr><td>Gross in",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "274b9d8b20bbcaa5",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0ppt</td></tr><tr><td>APAC</td><td>0.9%</td><td>6.0%</td><td>6.0%</td><td>5.0%</td><td>6.0%</td><td>6.0%</td><td></td><td>-4.1ppt</td><td>-0.0ppt</td><td>-0.0ppt</td></tr><tr><td>Gross income adjusted",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "957f37d7cb2eb177",
        "value": 0.006,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>6,528</td><td>6,861</td><td>7,238</td><td>6,492</td><td>6,836</td><td>7,202</td><td></td><td>0.6%</td><td>0.4%</td><td>0.5%</td></tr><tr><td>Margin</td><td>37.9%</td><td>38.1%</td><td>38.3%</td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "0a8887d81aa022f6",
        "value": 0.004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>6,861</td><td>7,238</td><td>6,492</td><td>6,836</td><td>7,202</td><td></td><td>0.6%</td><td>0.4%</td><td>0.5%</td></tr><tr><td>Margin</td><td>37.9%</td><td>38.1%</td><td>38.3%</td><td>37.8%</t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "58fbf1644aa7c794",
        "value": 0.005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>7,238</td><td>6,492</td><td>6,836</td><td>7,202</td><td></td><td>0.6%</td><td>0.4%</td><td>0.5%</td></tr><tr><td>Margin</td><td>37.9%</td><td>38.1%</td><td>38.3%</td><td>37.8%</td><td>38.0%</",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "ed8fcf90c24e1ef6",
        "value": 0.379,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6,836</td><td>7,202</td><td></td><td>0.6%</td><td>0.4%</td><td>0.5%</td></tr><tr><td>Margin</td><td>37.9%</td><td>38.1%</td><td>38.3%</td><td>37.8%</td><td>38.0%</td><td>38.2%</td><td></td><td>0.1ppt<",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "af9e5f59fc4e1ef5",
        "value": 0.381,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7,202</td><td></td><td>0.6%</td><td>0.4%</td><td>0.5%</td></tr><tr><td>Margin</td><td>37.9%</td><td>38.1%</td><td>38.3%</td><td>37.8%</td><td>38.0%</td><td>38.2%</td><td></td><td>0.1ppt</td><td>0.1ppt",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "c95490e14fbd1c8c",
        "value": 0.38299999999999995,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>0.6%</td><td>0.4%</td><td>0.5%</td></tr><tr><td>Margin</td><td>37.9%</td><td>38.1%</td><td>38.3%</td><td>37.8%</td><td>38.0%</td><td>38.2%</td><td></td><td>0.1ppt</td><td>0.1ppt</td><td>0.1pp",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "a0bca936458aeecf",
        "value": 0.37799999999999995,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>0.4%</td><td>0.5%</td></tr><tr><td>Margin</td><td>37.9%</td><td>38.1%</td><td>38.3%</td><td>37.8%</td><td>38.0%</td><td>38.2%</td><td></td><td>0.1ppt</td><td>0.1ppt</td><td>0.1ppt</td></tr><tr",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "c8aa4527000ce426",
        "value": 0.38,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>0.5%</td></tr><tr><td>Margin</td><td>37.9%</td><td>38.1%</td><td>38.3%</td><td>37.8%</td><td>38.0%</td><td>38.2%</td><td></td><td>0.1ppt</td><td>0.1ppt</td><td>0.1ppt</td></tr><tr><td>EBITDA ad",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "c7dc9db0b473602f",
        "value": 0.382,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>Margin</td><td>37.9%</td><td>38.1%</td><td>38.3%</td><td>37.8%</td><td>38.0%</td><td>38.2%</td><td></td><td>0.1ppt</td><td>0.1ppt</td><td>0.1ppt</td></tr><tr><td>EBITDA adjusted</td><td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "ef26d52a5f7ecbaf",
        "value": 0.017,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>3,373</td><td>3,590</td><td>3,802</td><td>3,316</td><td>3,529</td><td>3,743</td><td></td><td>1.7%</td><td>1.7%</td><td>1.6%</td></tr><tr><td>Margin</td><td>19.6%</td><td>19.9%</td><td>20.1%</td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "c3dbfa952c415197",
        "value": 0.017,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>3,590</td><td>3,802</td><td>3,316</td><td>3,529</td><td>3,743</td><td></td><td>1.7%</td><td>1.7%</td><td>1.6%</td></tr><tr><td>Margin</td><td>19.6%</td><td>19.9%</td><td>20.1%</td><td>19.3%</t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "dbac08e838f83ba0",
        "value": 0.016,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>3,802</td><td>3,316</td><td>3,529</td><td>3,743</td><td></td><td>1.7%</td><td>1.7%</td><td>1.6%</td></tr><tr><td>Margin</td><td>19.6%</td><td>19.9%</td><td>20.1%</td><td>19.3%</td><td>19.6%</",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "2880922d3f2afa52",
        "value": 0.196,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "3,529</td><td>3,743</td><td></td><td>1.7%</td><td>1.7%</td><td>1.6%</td></tr><tr><td>Margin</td><td>19.6%</td><td>19.9%</td><td>20.1%</td><td>19.3%</td><td>19.6%</td><td>19.8%</td><td></td><td>0.3ppt<",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "11dac4533bebadcf",
        "value": 0.19899999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "3,743</td><td></td><td>1.7%</td><td>1.7%</td><td>1.6%</td></tr><tr><td>Margin</td><td>19.6%</td><td>19.9%</td><td>20.1%</td><td>19.3%</td><td>19.6%</td><td>19.8%</td><td></td><td>0.3ppt</td><td>0.3ppt",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "aeef9a7a22faf2cd",
        "value": 0.201,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>1.7%</td><td>1.7%</td><td>1.6%</td></tr><tr><td>Margin</td><td>19.6%</td><td>19.9%</td><td>20.1%</td><td>19.3%</td><td>19.6%</td><td>19.8%</td><td></td><td>0.3ppt</td><td>0.3ppt</td><td>0.3pp",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "e292119bc3664b36",
        "value": 0.193,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>1.7%</td><td>1.6%</td></tr><tr><td>Margin</td><td>19.6%</td><td>19.9%</td><td>20.1%</td><td>19.3%</td><td>19.6%</td><td>19.8%</td><td></td><td>0.3ppt</td><td>0.3ppt</td><td>0.3ppt</td></tr><tr",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "e0c392e5292a0d13",
        "value": 0.196,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>1.6%</td></tr><tr><td>Margin</td><td>19.6%</td><td>19.9%</td><td>20.1%</td><td>19.3%</td><td>19.6%</td><td>19.8%</td><td></td><td>0.3ppt</td><td>0.3ppt</td><td>0.3ppt</td></tr><tr><td>EBIT adju",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "1f9ae1cc9ab0b839",
        "value": 0.198,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>Margin</td><td>19.6%</td><td>19.9%</td><td>20.1%</td><td>19.3%</td><td>19.6%</td><td>19.8%</td><td></td><td>0.3ppt</td><td>0.3ppt</td><td>0.3ppt</td></tr><tr><td>EBIT adjusted</td><td>1",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "c43cfe2b00757d28",
        "value": -0.016,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>1,987</td><td>2,154</td><td>2,317</td><td>2,020</td><td>2,185</td><td>2,350</td><td></td><td>-1.6%</td><td>-1.4%</td><td>-1.4%</td></tr><tr><td>Margin</td><td>11.5%</td><td>11.9%</td><td>12.2%<",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "55650caae0a0945e",
        "value": -0.013999999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>2,154</td><td>2,317</td><td>2,020</td><td>2,185</td><td>2,350</td><td></td><td>-1.6%</td><td>-1.4%</td><td>-1.4%</td></tr><tr><td>Margin</td><td>11.5%</td><td>11.9%</td><td>12.2%</td><td>11.8%<",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "60d2abd2d39c3d2b",
        "value": -0.013999999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>2,317</td><td>2,020</td><td>2,185</td><td>2,350</td><td></td><td>-1.6%</td><td>-1.4%</td><td>-1.4%</td></tr><tr><td>Margin</td><td>11.5%</td><td>11.9%</td><td>12.2%</td><td>11.8%</td><td>12.1%<",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "23c2996665c3410e",
        "value": 0.115,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "85</td><td>2,350</td><td></td><td>-1.6%</td><td>-1.4%</td><td>-1.4%</td></tr><tr><td>Margin</td><td>11.5%</td><td>11.9%</td><td>12.2%</td><td>11.8%</td><td>12.1%</td><td>12.4%</td><td></td><td>-0.2ppt",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "82686cce604d2830",
        "value": 0.11900000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "50</td><td></td><td>-1.6%</td><td>-1.4%</td><td>-1.4%</td></tr><tr><td>Margin</td><td>11.5%</td><td>11.9%</td><td>12.2%</td><td>11.8%</td><td>12.1%</td><td>12.4%</td><td></td><td>-0.2ppt</td><td>-0.2p",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "24a0d6bd7cdd0b0b",
        "value": 0.3,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "hodology: We derive our PT for Elekta using a blend of c.12x PE and 8x EV/EBITDA on Apr'26E, or a c.30% discount to peers, which we see as justified given a poor track record of execution and downside",
        "provenance": {
          "page": 14
        }
      },
      {
        "num_id": "16c5c07d4a1152a2",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ur price target based on a blend of 2025E P/E (29x) and EV/EBITDA (16x) multiples, representing a c.8% premium to MedTech peers. We believe SHL is a high-quality name that warrants a premium, supporte",
        "provenance": {
          "page": 16
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 0,
      "tables_count": 0,
      "numerical_data_count": 135,
      "passages_count": 118,
      "entities_count": 20
    }
  }
}